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ABSTRACT
Patient Preferences for Benefits and Risks Associated with Disease Modifying Drugs in
Multiple Sclerosis

Abhijeet J. Bhanegaonkar

Multiple sclerosis (MS) is a chronic inflammatory demyelinating neurological disorder with no
known cure. Disease modifying drugs (DMDs) used in the treatment of MS reduce the
frequency relapses and delay the progression of the disease. Although DMD therapy is the
mainstay of treatment of MS, it is associated with variety of side effects and severe adverse
events. A majority of currently available DMDs are injectable, except one which is available in
the pill form. Therapeutic decisions in MS are challenging due to the inconvenience of
administration, frequency of administration, longer duration of therapy, side effects, and risk of
adverse events associated with DMDs. The purpose of this series of studies was to better
understand different aspects of DMDs from patients’ point of view. A total of three studies
were conducted using qualitative and quantitative research methods. Data for the first study
were collected using focus group interviews among eighteen MS patients attending neurology
clinic affiliated to a teaching hospital. Study two and study three were performed using a webbased survey questionnaire in a sample of MS patients residing in the United States using a
cross-sectional study design. The specific objectives are the three studies were: 1) To explore
patients’ experiences, opinions, and expectations related to DMDs used in MS, 2) to estimate
preference weights and relative importance of attributes for DMDs used in MS treatment using
conjoint analysis, and 3) to assess disease and treatment related factors associated satisfaction
with treatment among MS patients. Participants in the first study had an understanding of
importance of DMDs in the therapeutic management of MS. MS patients reported to adapt
themselves to available DMD choices, but had greater expectations from emerging DMDs.
Participants reported that the convenience of DMD administration, occurrence of relapses,
delay of disability progression were important factors related to DMD; however, most were
concerned about the side-effects that affected day-to-day functioning and the adverse events
associated with DMDs. The results of the second study revealed that attributes indicating risks
associated with DMDs (progressive multifocal leukoencephalopathy and severe liver
dysfunction) were the most important attributes followed flu-like symptoms, delaying disability
progression, frequency of relapses, and mode of DMD administration. Strength of evidence on
treatment outcomes expressed in number of years was the least important attribute to
patients. The results of the third study indicated that factors such as type of current DMD used,
relapses experienced, disability status, total number of MS symptoms experienced, and past
experiences with DMDS were associated with lower treatment satisfaction scores.
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CHAPTER 1
INTRODUCTION

Overview of Multiple Sclerosis
Multiple sclerosis (MS) is a chronic demyelinating inflammatory neurological disorder
which affects the white matter of the brain, spinal cord, and optic nerves. MS is characterized
by neurological episodes followed by remission with unpredictable relapses. Varying degrees of
functional impairments and disabilities are observed in MS patients depending on the site and
magnitude of lesions/damage in the brain, spinal cord, and optic nerve.
Etiology/Pathogenesis of MS
The cause and the exact pathogenesis of MS is not yet completely understood.
However, epidemiological studies indicate several environmental and genetic factors to be
associated with development, as well as outcomes of MS. It is hypothesized that development
of MS takes place in genetically susceptible individuals after being exposed to certain
environmental factors (Ramagopalan, 2010).
a. Genetic risk factors:
Genetic epidemiological studies have revealed importance of role played by genetic factors
in susceptibility to MS (Dyment, 2004). Although MS is not considered to be a genetic
disorder, several specific genes are linked to an increase in the risk of developing MS.
Although not directly associated, certain Human Leukocyte Antigen (HLA) types are found to
have strong genetic effect in MS (Ramagopalan, 2010). These haplotypes may solely be
associated with MS or may affect susceptibility to MS in combination with other haplotypes
2

(Dyment, 2005; Masterman, 2000; Barcellos, 2006; Ramagopalan, 2007). Studies looking at
genetic factors associated with MS indicated moderate effects of genes such as interleukin7 receptors α (IL7RA), interleukin-2 receptor α (IL2RA), C-type lectin-domain family 16
member A (CLEC16A), CD58 (Formerly lymphocyte function-associated antigen 3; CD58),
tumor-necrosis-factor receptor superfamily member 1A (TNFRSF1A), interferon regulatory
factor 8 (IRF8), and CD6 (CD6) on increased susceptibility as well as disease outcomes (De
Jager, 2009). Various genes, not limited to above mentioned list, may act independently or
interactively with other environmental factors to develop MS. As MS is commonly seen
among women, sex hormones are considered to play a crucial role in developing MS (Coo,
2004). Caucasians with their origins in Scandinavia and Scotland have very high
susceptibility to MS compared to individuals with other racial origins (Milo, 2010). Such
observations in various studies have led researchers to dig deeper into genetic etiology of
MS. In families with a history of MS, it is more likely for the first, second, and third degree
relatives to develop MS as compared to the general population (Dyment, 2004). Also, the
risk of developing MS is higher in blood relatives such as siblings, parents, and children.
Monozygotic twins (identical) have higher risk of developing MS as compared to dizygotic
twins (Fraternal) (Hansen, 2005).
b. Environmental risk factors:
Causation studies have indicated several environmental risk factors that can have a
potential role in the development of MS in a susceptible population. However, these
factors can neither be a necessary nor a sufficient cause in the development of MS (Raine,
2008). Occupational exposure to toxins mainly organic solvents has been found to increase
3

the chances of developing MS although the evidence on this is weak (Marrie, 2004).
Decreased exposure to sun is considered to increase the risk of MS (Marrie, 2004). MS is
much less common in people living near the equator (Alonso, 2008; Compston, 2008).
Emotional stress is also considered to be a risk factor although the evidence is weak
(Marrie, 2004). Some of the other factors which are thought to be the causal factors for MS
are vaccination (Marrie, 2004), diet (Ghadirian, 1998), smoking (Ascherio, 2007), and being
born in the spring (Willer, 2005). Various infectious agents are also proposed to be the risk
factors for MS. Higher levels of human herpes virus (HHV) antibodies (Caselli, 2002; Soldan,
1997) and HHV-6 DNA (Álvarez-Lafuente, 2002; Tejada-Simon, 2002) were found in the
blood serum of patients with MS as compared to the control subjects. Epstein-Barr virus
(EBV) is also considered to be relevant to MS as antibodies to this virus have been found are
at higher levels than expected among the MS patients (Levin, 2003). Past infections such as
measles, mumps, and rubella are also linked to MS (Compston, 2008).
Pathophysiology of MS
Current understanding of the underlying pathophysiology of MS suggests that the
myelin sheath protecting the axon is targeted by the autoimmune inflammatory system in the
body for destruction leading to a demyelination process. The myelin sheath is composed of
lipid and has the important function of insulating the axon and helping in nerve signal
conduction. It is hypothesized that the demyelination process takes place when inflammatory
mediators from the circulating blood enter through a damaged blood brain barrier (BBB) and
disrupt the myelin sheath present on neurons. This destruction is carried out by an
overproduction of cytokines like tumor necrosis factor alpha and lymphotoxin alpha that trigger
4

specific reactions within the myelin sheath and contribute to myelin damage by the immune
system (Ledeen, 1998). The demyelination process results in axonal damage and death by
hampering the efficiency of electrical conduction through the neural network within parts of
the central nervous system (Trapp, 1998). Demyelination is characterized by scars and
hardened areas on parts of the central nervous system (CNS) and these areas are known as
lesions. The magnitude of demyelination, resolution of the attack, and remyelination
determines the impact, duration of symptoms, and the time required to heal following an
attack (Trapp, 1998). The myelin sheath rebuilt by the process of remyelination is not as
effective as the original myelin sheath. The inability of nerves to conduct electrical signals as a
result of demyelination and inflammation leads to various CNS related symptoms.
Types of MS
Predicting the course of MS is a challenge due to the variability in symptoms and
progression of the disease. However, following four major clinical subtypes are used to describe
prognosis of MS and are frequently used for making clinical decisions.
a. Relapsing remitting multiple sclerosis (RRMS) – RRMS is the most common subtype of MS
with approximately 80-85% patients diagnosed with this subtype at the initial diagnosis of
the disease. The rest of the MS diagnoses at onset are of primary progressive multiple
sclerosis (PPMS) (Bell, 2007; Kidd, 2001). RRMS is characterized by periodic and clearly
defined attacks followed by full or partial recovery. The period between two attacks are
characterized by a lack of new symptoms, although the underlying disease process may be
continuing.
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b. Primary progressive multiple sclerosis (PPMS) – Patients with PPMS experience gradual
worsening after the onset of the disease. PPMS is characterized by indistinct relapses and
remissions after the onset of MS.
c. Secondary progressive multiple sclerosis (SPMS) – This is a major progressive subtype of
MS. Approximately 80% of the RRMS patients experience a progression of their disease
within 7-15 years to secondary progressive multiple sclerosis (SPMS) characterized by a
sudden decline in neurological function without any remission (Willer, 2000). According to
a National Institute for Health and Clinical Excellence (NICE) 2003 report, almost 50% of
patients who experience RRMS develop SPMS 10 years after onset, and 90% after 25 years
from initial diagnosis (NICE, 2003; Weinshenker, 1989).
d. Progressive relapsing multiple sclerosis (PRMS) – In this subtype, the patient experiences
worsening progression of MS from the initial diagnosis marked by superimposed relapses
and remissions. The progressive phase of multiple sclerosis is dominated by disability that
accumulates over the course of disease.
Symptoms
A patient with MS or possible MS may present with the following clinical symptoms:
a. Primary symptoms are fatigue, weakness, numbness, gait disturbances, visual disturbances,
dizziness, ataxia, bladder and bowel problems, changes in sexual function, cognitive
problems, pain and muscle weakness, spasm, and spasticity (Gulick, 1998; Rao, 2004;
Schapiro, 1997).
b. Secondary symptoms occur as an implication of primary symptoms. These symptoms may
include obesity, contractures, and urinary tract infections (Schapiro, 1997).
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c. Tertiary symptoms stem from psychological (depression due to MS), vocational (inability to
perform job related functions) and social (relationship problems) effects of MS (Schapiro,
1997).
The magnitude of demyelination and damage to the axon determines the clinical
symptoms. Studies have shown that approximately one half of MS patients will require some
type of walking aid within 15 years of the onset of MS. Approximately 10% will require
wheelchair assistance. Approximately 90% will have significant disability and functional
limitations within 25 years of onset of MS (Kieseier, 2003; Weinshenker, 1989).
Prevalence
According to the National Multiple Sclerosis Society, prevalence of MS in the United
States (US) is 400,000 or approximately 135 per 100,000 population. Epidemiological studies
from different geographical areas have provided a wide range of prevalence estimates for MS in
the US. The accuracy of these estimates is limited by the fact that incidence rates are higher in
the north as compared to the south. Regional variation in the occurrence of MS is explained by
higher incidence of MS in regions with temperate climate compared to the tropical regions.
Prevalence of MS is often higher in the regions north of 40 degrees latitude and away from
equator (Kurtzke, 1977). Based on various studies, the incidence rate ranges from 85-177
adults per 100,000 population in the US (Bell, 2007). Prevalence of MS in women is observed to
be twice as much as that of men, with the recent data suggesting a continuous increase in the
prevalence of MS in women recently (Noonan, 2002).
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Economic, Clinical, and Humanistic Burden of MS
Early onset of disabilities (between 20-40 years of age) and lifelong nature of MS impose
considerable burden on patients, their families, and the society (Prescott, 2007). Despite being
an incurable disease and a cause for chronic disability, life expectancy of patients is not affected
by MS. Costs associated with medical care (drug treatment, hospitalizations, hospital visits for
routine check-up, and physical therapy), care provided by non-professionals (family and
friends), loss of work productivity (long and short term sick leave and early retirement), and
other non-medical care contribute greatly to the direct cost of care of MS patients (Kobelt,
2006). Total annual medical and lost productivity costs associated with MS was estimated to be
approximately $28 billion in the US (Society for Neuroscience, 2011). The lifetime (direct and
indirect) cost for an individual with MS was estimated to be $2.2 millon (Goldstein, 1998).
Treatment costs represent a significant portion of the total cost of MS. In 2007, the cost
associated with disease modifying drug (DMD) treatment was reported to be approximately
$2,000 per month (Kunze, 2007). Impaired physical functioning, health-related quality of life
(HRQoL), social and emotional well being, and family relationships account for the intangible
costs of MS.
Patients with MS experience lower quality of life (QoL) compared to the patients with
other chronic illnesses, such as, diabetes, arthritis, and epilepsy (Hermann, 1996). The lower
HRQoL in MS is mainly due to the decrementing effects on patients’ physical, neurological,
psychiatric, and psychological functioning on a daily basis. Multiple sclerosis substantially
influences family, work, and social aspects of life of an individual (Solari, 2001). With a
progressive disease course, patients with MS face challenges in accomplishing tasks associated
8

with daily living on their own and often require structural changes in the house and nonprofessional/professional care (Stenager, 1994). The attacks and remission periods in MS are
unpredictable, which makes coping with MS difficult. Disease management in MS is highly
demanding and inflicts substantial burden on patients and their families. The well-being of MS
patients is severely affected due to risk of losing independence, personal autonomy, dignity,
and future plans over time (Boeije, 2002). Apart from physical disability and distress, MS
patients also suffer from considerable neuropsychiatric burden (Mitchell, 2005). Individuals
with MS are highly susceptible to developing psychiatric symptoms and disorders especially,
depression and anxiety (Chwastiak, 2007). Psychological, social, and psychiatric domains of
HRQoL are increasingly utilized along with physical disability assessment to model the global
impact of disease.
Disease Modifying Drugs
Over the last two decades, a significant increase in the understanding of molecular and
cellular mechanisms of immune cell activation and passage through the blood brain barrier into
the central nervous system has resulted in an evolution of disease modifying treatment options
in MS. The last three decades have seen the growth of anti-inflammatory treatment strategies
aimed at treating the inflammatory nature of acute lesions in MS. Immunological treatments
have gained prominence in recent years due to the increasing understanding of disease
pathogenesis and the need to provide selective therapeutic interventions for MS.
Currently, the following six disease modifying drugs (DMDs) are approved by the U.S.
Food and Drug Administration (FDA) for the treatment of multiple sclerosis.
-

Interferon-β-1a (Avonex®, Biogen; Rebif®, Pfizer-Serono)
9

-

Interferon-β-1b (Betaseron®, Berlex; Extavia®, Novartis)

-

Glatirimer acetate (Copaxone®, Teva)

-

Natalizumab (Tysabri®, Biogen)

-

Fingolimod (Gilenya®, Novartis)

-

Mitoxantrone (Novantrone®, Novartis)

Two major goals of pharmacotherapy of MS are to:
a. Reduce the frequency and severity of relapses, and
b. Delay the onset of the progressive stage and resultant disability due to multiple sclerosis
(Thompson, 2001).
Interferon-β and glatiramer acetate are immunomodulatory agents that are considered
to be the primary treatment of choice among patients with relapsing remitting multiple
sclerosis. These agents are known to shift the pro-inflammatory autoimmune responses to a
more favorable anti-inflammatory response, often without affecting the immune status of the
patient (Neuhaus, 2007).
Several mechanisms of action are hypothesized for Interferon-β in multiple sclerosis.
Interferons affect disease activity by preventing T-lymphocytes from crossing the blood brain
barrier (Leppert, 1996; Stuve, 1996; Yong, 1998) by limiting T-cell activation within the central
nervous system (CNS) (Frohman, 2005) and production of pro-inflammatory cytokine tissue
necrosis factor α associated with T-cells (Chabot, 1997). Treatment efficacy of interferons is
supported by positive findings on magnetic resonance imaging (MRI) indicating a significant
drop in total active lesions and total lesion load (Li, 1999; Paty, 1993). Interferons are found to
reduce the relapse frequency by one third and attenuate the gravity of exacerbations (Polman,
10

2000). Interferon-β- 1a (Avonex®) (US FDA 2008 Avonex®package insert) is administered
intramuscularly once a week whereas Interferon-β- 1a (Rebif®) is administered subcutaneously
three times per week (US FDA 2008 Rebif®package insert). Interferon-β- 1b (Betaseron®) is
injected subcutaneously every other day (US FDA 2008 Betaseron®package insert).
Glatiramer acetate acts by binding with the major histocompatibility complex (MHC)
and blocks the presentation of various myelin antigens to the T-cells (Arnon, 2004). It also
produces glatiramer specific T-cells, which specifically suppress T-helper 2 (Th2) cells that enter
the brain and suppress the autoimmune response against myelin (Gonsette, 2004). In a two
year, multicenter, randomized control trial, glatiramer acetate showed a 29% annual decrease
in the frequency of relapses. Glatiramer acetate is administered subcutaneously once each day
(US FDA 2008 Copaxone®package insert).
Natalizumab, a humanized monoclonal antibody, is the first drug from the selective
adhesion molecule inhibitor class used in the treatment of relapsing forms of MS (Polman,
2006; Giovannoni, 2007). Natalizumab inhibits the interaction of α4-integrin present on the
white blood cells (mononuclear leukocytes) with the vascular cell adhesion molecule-1(VCAM1) expressed on the surface of cerebral endothelial cells, thereby preventing leukocytes from
entering into the CNS (Yednock, 1992). In a phase III trial, natalizumab monotherapy resulted in
significant reduction (68%) in annual relapse rates and delayed accumulation of physical
disability by 42% over a two year time period (Polman, 2006). Natalizumab is administered by
intravenous infusion every month (US FDA 2008 Tysabri® package insert).
Fingolimod is the first oral DMD available for MS patients. It is a sphingosine 1phosphate receptor modulator which is structurally similar to naturally occurring sphingosine
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molecule (Chun, 2010). It is thought to activate lymphocytes S1P1 resulting in preventing exit of
the lymphocytes from the lymph nodes (Chun, 2010). This reduces penetration of lymphocytes
through the blood brain barrier into the central nervous system.
Mitoxantrone is an antineoplastic immunosuppressive agent and is the first approved
treatment for worsening forms of multiple sclerosis, especially among younger patients with
relapsing remitting multiple sclerosis or those who present with early secondary progressive
multiple sclerosis (Cohen, 2004). It is the preferred treatment among patients not responding
to first line of therapy and who continue to experience declining neurological function and
progressive disability. A distinct immunological effect makes it the preferred treatment among
patients who do not respond to other immunomodulatory treatments. The mechanism of
action for mitoxantrone involves disruption of DNA synthesis leading to extended cell-cycle
progression (Smith, 1983). It is known to exert its immunosuppressive effects in MS by
hampering production of immune cells, such as T-lymphocytes, B-lymphocytes, and
macrophages (Mauch, 1992; Fidler, 1986). Mitoxantrone also initiates programmed cell death
of antigen presenting cells (Neuhaus, 2005) and B-lymphocytes (Bellosillo, 1998). In a large two
year multicenter, randomized, placebo-control, investigator blinded trial, mitoxantrone
demonstrated a significant reduction in relapse rate, disease progression (Hartung, 2002), and
lesion load (Krapf, 2005). Mitoxantrone is injected intravenously and the drug is administered
once every three months for two to three years (US FDA 2008 Novantrone® package insert).
Emerging Treatments
In spite of the above mentioned treatment choices, difficulties in decision making
related to selection of DMD treatment in MS continue to persist for both, neurologists and
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patients. Although the primary treatment choices (IFN-βs and glatiramer acetate) are safe to
administer, their long term efficacy remains unknown. Mitoxantrone, Natalizumab, and the
more recently approved DMD Fingolimod, exhibit significant efficacy in active MS, but are
limited in their use due to adverse drug events associated with them. Neurodegeneration and
lack of regeneration of injured CNS tissue is recognized as the crucial factor in predicting the
course of disability among MS patients. With an increasing understanding and knowledge of
the mechanisms of immune cell migration and activation, targeting specific immunological
responses is now emerging as the primary focus of newer therapeutic strategies under
investigation (Frohman, 2005). Therefore, future pharmacotherapy will be largely focused on
neuro-protection and neuro-repair.
Another approach proposed for treatment of MS is the use of two or more drugs with
independent mechanisms of action targeting different steps in the MS pathway (Costello,
2007). Synergistic or additive therapeutic effect of combination therapies has been observed to
improve clinical outcomes in other chronic autoimmune diseases like rheumatoid arthritis
(Wingerchuk, 2008). Preliminary outcomes and safety profile of few combination therapies
including IFN-βs and/or glatiramer acetate with other drugs in short term studies in MS patients
have been promising (Gonsette, 2004).
Various alternative therapies with an oral route of administration and novel modes of
action have shown a significant and consistent effect on both clinical relapses and MRI
measures (Cohen, 2007). Future DMDs are expected to provide novel mechanism of actions
resulting in improved clinical effectiveness, and better safety profiles, along with convenient
routes of administration and improved administration devices. Treatments with a less invasive
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route of administration are expected to improve patient satisfaction, treatment adherence, and
resultant therapeutic efficacy.

Need for Study
Study 1 – Need for understanding opinions, experiences, and expectations of MS patients
regarding DMDs and MS (Focus Group Method)
Current research in MS is targeted toward improving pathophysiological understanding
of the underlying disease and development of new, efficacious, safe, and tolerable treatment
strategies capable of altering the disease course and address the symptoms. Despite several
advances in the field of MS, patients still continue to live with various needs and concerns as
they experience increasing physical, psychological, and socio-economic burden associated with
the disease. The requirements and expectations of MS patients are diverse due to the
heterogeneity of the disease, symptoms, treatment, and several other MS related factors.
Multiple sclerosis is a chronic disease without a known cure that requires long term treatment.
Adherence to prescribed pharmacotherapy is an important predictor of treatment success
(Cramer, 1998). Low adherence hinders optimal clinical efficacy of treatment (Dunbar-Jacob,
2000). All of the DMDs currently used for treating MS are administered parenterally except for
one DMD which is administered orally. Factors like needle phobia (Cox, 2006), difficulty in self
injecting (Cox, 2006), injection site reactions (Panitch, 2002; Samuel, 2006), and discomfort in
self injecting (Rio, 2005; Cramer, 2006) are commonly reported by MS patients. All these
factors are also known to reduce treatment adherence significantly among MS patients.
Challenges associated with DMD medications not only affect patients’ satisfaction with the
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treatment but also influence behaviors pertaining to stopping and switching treatments, and
most importantly lower treatment adherence. Studies evaluating adherence and factors
influencing adherence to DMDs in multiple sclerosis patients have indicated that a significant
number of patients discontinue therapy within the first six months after initiation of therapy
(Mohr, 1996; Tremlett, 2003). Similar trends were observed up to the first two years after
starting the DMD treatment in a study done by Rio et al. (Rio, 2005). None of the previously
published studies have attempted to understand qualitative experiences of MS patients with
respect to DMDs, thus qualitative approach of focus group discussions is an effective way to
obtain a deeper understanding of different dimensions associated with DMDs that MS patients
often experience.
Study 2 – Need for evaluating MS patient preferences for DMDs (Stated Preference Method –
Conjoint Analysis)
Disease modifying agents approved by the US FDA during the last decade were
perceived as a hope for better treatment outcomes in MS. These agents provided physicians
and patients a wider treatment choice, often necessitating them to make a series of trade-offs
on the important attributes of therapeutic management. Although clinical efficacy
characteristics, such as time to next relapse and slowed disability progression are the key
elements of preferred treatment, patients’ valuation for a treatment choice may also be
influenced by other characteristics such as nature, frequency, administration convenience, cost
of the treatment, adverse drug events, and other side effects. Previous studies have reported
general dissatisfaction with treatment and care in MS patients. This dissatisfaction with
treatment may reflect a failure to understand patient preferences while selecting a DMD.
15

Therefore it is important to evaluate patient preferences for DMDs in the treatment of MS.
This study will provide an opportunity to quantify the value that MS patients put on the
benefits and risks of DMDs. This information will also help clinicians and patients in making
decisions with respect to MS treatment.
Study 3 – Need for evaluating factors associated with treatment satisfaction in MS patients
The individual and societal burden of MS is significant, especially due to the prevalence
of early onset of disabilities, usually between the ages of 20 to 40 years (Prescott, 2007). These
are the years which are considered to be the most productive working years in people’s lives.
The chronic and incurable nature of MS also adds substantially to this burden. Patients with MS
are affected in several ways based on the magnitude of neurological impairment and resultant
changes in associated aspects of life. Approximately 50% of the MS patients become unable to
fulfill job and household related responsibilities, one half of MS patients require some type of
walking aid within 15 years of onset of MS, and 50% require wheelchair assistance within 25
years of onset of MS (Confavreux, 2000). Costs associated with productivity loss contribute
significantly towards the total costs of MS (Kobelt, 2006). DMDs used in the therapeutic
management of MS are the mainstay therapies known to reduce frequency of relapses thereby
stopping or delaying the worsening of MS and the resultant accumulation of the disability.
Adherence to DMDs is a major challenge in the therapeutic management of MS. Nonadherence to DMDs among MS patients is associated with DMD related factors such as
perceived or experienced lack of efficacy, injection site reactions, pain at injection sites, side
effects associated with DMDs, difficulty in self-injecting, and not being able find someone to
give injection (Treadaway, 2009). Although studies have been done to assess patient
16

satisfaction with specific injection devices (Cramer, 2006), information on factors affecting
treatment satisfaction in a large sample of MS patients using different DMDs is still lacking.
Given the potential for DMDs to influence different aspects MS patients’ lives, it is essential to
fill the current knowledge gaps with respect to treatment satisfaction in MS patients.
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CHAPTER 2

UNDERSTANDING PATIENTS’ PERSPECTIVES ON DISEASE MODIFYING DRUGS USED IN
MULTIPLE SCLEROSIS - A QUALITATIVE STUDY

Abstract
Objective: The purpose of this qualitative study was to explore patients’ experiences, opinions,
and expectations related to disease modifying drugs (DMDs) used in multiple sclerosis (MS).
Methods: A sample of 18 individuals with confirmed diagnosis of MS was recruited through a
university hospital-based neurology clinic. Four focus group (FG) sessions involving semistructured interviews were conducted. The FG discussions were audio-recorded and were later
transcribed for coding purposes. Qualitative content analysis of transcribed data was
performed by two blinded reviewers using QSR NVivo 8 software. The data were coded into
specific themes as per the research questions.
Results: Qualitative analysis indicated five major themes related to experiences with existing
DMDs and expectations from the future DMDs: positive experiences of DMDs, negative
experiences of DMDs, adherence, perceived/actual value of DMD, and expectations from future
DMD. Although a majority of the participants had experienced side effects associated with
injectable DMDs, they were generally content with clinical benefits associated with DMDs they
were currently taking. Future DMDs were expected to be safer and easier to administer.
Conclusions: This study provides an in-depth understanding of various factors associated with
DMDs that are important to MS patients. With increasing number of treatment choices, MS
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patients’ involvement in complex treatment decisions will become even more crucial. In order
to select the best possible treatment for MS patients, it is imperative to choose a treatment
that is clinically effective, while keeping their preferences and needs in mind. Improving
patients’ knowledge about benefits and risks of DMDs and allowing them to actively participate
in making informed treatment decisions will be increasingly important and challenging with
respect to future treatment.
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Introduction
Multiple sclerosis (MS) is a progressive demyelinating inflammatory disorder affecting
the central nervous system involving the white matter of the brain, spinal cord, and optic
nerves. Approximately 400,000 individuals in the United States (US) are currently affected by
this chronic debilitating neurological condition (NMSS, 2011). It mainly affects young adults
between the ages of 20 and 40 (Confavreux, 1980). It is the major cause of non-traumatic
disability among young adults in the US (Dutta, 2007).
MS is characterized by worsening of physical and cognitive abilities in an affected
individual over the long course of the disease. At the initial diagnosis, approximately 85% of MS
patients are diagnosed with the relapsing remitting multiple sclerosis (RRMS) subtype which is
characterized by periodic and clearly defined attacks, also known as relapse, followed by full or
partial recovery (Rudick, 2008). With the passage of time, recovery from each relapse remains
incomplete resulting in a gradual accumulation of physical and cognitive deficits (Weinshenker,
1989; Lublin, 1996; Coles, 2009). A majority of the RRMS patients experience progression of
their MS within 7-15 years following RRMS onset to the secondary progressive multiple
sclerosis (SPMS), which is characterized by a gradual and continuous decline in neurological
functions without any relapse (Weinshenker, 1989; Lublin, 1996; Coles, 2009). Approximately
15% of MS patients experience the progressive form of MS from the initial diagnosis, without
any preceding relapses (Rudick, 2008). Patients with primary progressive multiple sclerosis
(PPMS) never experience relapses, whereas those with progressive relapsing multiple sclerosis
(PRMS) do not experience any relapse after a gradual worsening at the onset but eventually
may experience relapses at a very low rate (Weinshenker, 1989; Lublin, 1996; Coles, 2009).
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Despite these different subtypes of MS, all MS patients experience declining quality of life over
the course of the disease as a result of decline in neurological functioning and the resultant
symptoms.
Currently, there is no known cure available for MS. However, over the last two decades,
a significant increase in the understanding of molecular and cellular mechanisms of immune cell
activation and passage through the blood brain barrier into the central nervous system has
resulted in an evolution of drugs for MS commonly known as disease modifying drugs (DMDs).
With the influx of various DMDs in the market, patients’ and clinicians’ perceptions have shifted
towards MS being a modifiable disease, and since then DMDs have become a vital part of the
therapeutic management of MS. DMDs help patients in maintaining neurological functions by:
a) reducing the frequency and severity of relapses, and b) delaying the onset of the progressive
stage and resultant disability due to MS (Thompson, 2001). There are currently seven DMDs (6
injectable and 1 oral) that are approved by the U.S. Food and Drug Administration (FDA) for the
treatment of MS. These DMDs are perceived as a hope for better treatment outcomes in MS.
Interferon beta-1a, Interferon beta-1b, and glatiramer acetate are considered to be the first
line of treatments that are relatively safer, but modestly efficacious. Other promising DMDs
like natalizumab, fingolimod, and, less used mitoxantrone, are usually considered as the second
line of treatments (Rudick, 2011). These DMDs are known to exhibit significant efficacy in
active MS, but are limited in their use due to adverse events associated with them. Several
other drugs have shown promising results in the late phases of drug development. Currently
available DMDs are shown in table 2.1. These DMDs provide physicians and patients with a
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wider treatment choice for therapeutic management of MS. However, the difficulty in selection
of a DMD still persists for neurologists and patients.
MS patients have reported needle phobia (Cox, 2006), difficulty in self-injecting (Cox,
2006), injection site reactions (Panitch, 2002; Samuel, 2006), and discomfort in self-injecting
(Rio, 2005; Cramer, 2006) as the common issues associated with injectable DMDs. Challenges
associated with DMD medications not only affect patients’ satisfaction with the treatment, but
also influence behavior pertaining to stopping and switching treatments, and most importantly
lower treatment adherence. Adherence to prescribed pharmacotherapy is an important
predictor of treatment success (Cramer, 1998). Low treatment adherence hinders optimal
clinical efficacy of treatment (Dunbar-Jacob, 2000).
Therefore, it is important to explore MS patients’ perspectives on DMDs. None of the
previously published studies have attempted to examine and understand subjective DMD
experiences among the MS patient population. The qualitative method is a valid approach to
identify aspects important among patients and to explore relevant meanings and beliefs
associated with those aspects (Sim, 1998). The objective of this study was to better understand
experiences, perceptions, and expectations among MS patients related to treatments with
DMDs.

Methods
Study Design
Data were collected using focus group interviews among individuals with multiple
sclerosis in a semi-structured interview format.
34

Participants
A purposive sample of 18 individuals was recruited for in-depth focus group discussion
sessions through the neurology clinic at the West Virginia University School of Medicine
(WVUSOM). Eligible individuals had to meet the following inclusion criteria: 1) at least 18 years
of age; 2) confirmed diagnosis of MS; 3) at least one visit to the outpatient neurology clinic at
WVUSOM within the last one year; 4) relapse-free at the time of participation; and 5) current
use of a DMD to treat MS. A list of probable candidates for focus group discussion was
prepared by the research nurse working in the neurology clinic using clinic records. Individuals
from this list were contacted via telephone by the neurology research nurse or the lead
researcher (AB) and a brief explanation of the study was provided. Eligible individuals
interested in focus group participation were sent an invitation letter with details of the study
including, date, time, and directions to the venue.
Procedure
The procedures for this research study were reviewed for human subject ethics
compliance and approved by the Institutional Review Board of West Virginia University. Semistructured focus group interviews were conducted. All discussion sessions were conducted and
moderated by the lead researcher (AB), which helped in controlling for interviewer bias. Each
discussion session was audio-recorded and data were transcribed verbatim. The study purpose
was explained to all participants and a consent form was administered to each individual.
Focus group discussions involved two parts. In the first part, participants were given a
brief questionnaire to complete. This questionnaire included questions related to sociodemographic information and individual disease and treatment history. All participants
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completed this questionnaire before beginning the discussions. In the second part, participants
were asked about their experiences with disease modifying drugs used in the treatment of MS,
in addition to other aspects such as health related quality of life, treatment satisfaction, health
concerns, and expectations from future disease modifying treatments for MS. Neurologists,
research nurses, and other members of the research team thoroughly reviewed the questions
in the interview guide prior to each focus group discussion session.
Each session was audio-recorded and individuals were asked to use an assigned number
to identify themselves each time before they spoke. During the focus group discussion,
whenever required, clarification on answers was sought from the participants in order to
correctly understand their treatment experiences. At the end of the focus group discussion,
each participant was provided a $25 Wal-Mart gift card as a token of appreciation for their
study participation. All focus group discussion sessions were moderated by the lead researcher
(AB) to control for interviewer effects (Blackwell, 2006). The moderator was not involved in the
clinical care of focus group participants, which allowed them to speak freely about their
experiences, opinions, and concerns with respect to their condition and treatments.
Analysis
Analysis involved a dynamic process of data collection and coding, where each of the
process helped to inform the next one. Audio-recorded data from each focus group were
immediately transcribed following the discussion session. The content was reviewed by the lead
researcher (AB) after each interview, which helped in reflecting upon the tentative categories.
Data collection ended after completion of the fourth focus group due to data saturation. There
was a significant amount and range of information to conduct formal analyses of all the
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transcripts collectively. Qualitative content analysis and coding of transcribed data were
performed by two blinded coders on the research team who analyzed the transcripts. Coding
and analysis were performed using Qualitative Solutions and Research (QSR) NVivo Version 8.0
software.
Coding procedures involved identification of meaningful phrases or quotes with respect
to the research questions. Terms describing the characteristics associated with each phrase or
quote were generated and identified as ‘codes’. Different categories were created to
encompass all the codes that were related to each other. These categories were modified and
broadened in scope to include different relevant aspects discussed by participants. Categories
which had similar or overlapping codes were merged wherever appropriate, or dropped when
found to be repetitious or redundant. Both coders compared respective codes and categories
after analyzing each transcript. This procedure was performed for the analysis of all four
transcripts. There was high concordance between codes and categories created by both the
coders after initial analysis. Wherever there were inconsistencies with respect to coding and
categorization, a resolution was reached by discussion and consensus with members of
research team. Opposing views of participants were used to determine the strength of results.
The next step in the analysis was to organize similarly coded phrases or quotes from all
transcripts. Once such pooling was done, all similarly coded content was carefully studied and a
brief description capturing extent and essence of that data was written using verbatim phrases
and quotes. Each category was refined using an iterative process. Analysis involved finding and
evaluating differing perspectives in the information shared by participants once a category was
developed. A total of five specific categories (key themes) emerged. Finally the entire research
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team was consulted in order to get their feedback on interpretation of the data and
conclusions. This process helped to avoid researcher bias and validate conclusions.

Results
Sample
Socio-demographic information is provided in table2.2. A total of 18 individuals with
confirmed diagnosis of MS participated in this study. Eleven participants were female and
seven participants were male. All participants were White and a majority of the participants
were married or were living with partners. The age of participants ranged from 26 years to 70
years with a mean age of ~49 years (SD=14.4). Almost all the participants had at least high
school level education. A majority of the participants were enrolled in publicly funded
insurance programs, such as Medicaid or Medicare. Nearly one half of the participants were
unable to work due their condition at the time of the study. Two thirds of the study
participants had a household income above $25,000.
Table 2.3 provides disease and treatment information for focus group participants. On
average, the disease duration was 11 years. Thirteen participants had been living with MS for
more than 5 years. A majority of the participants (66%) had relapsing remitting MS. Ten
participants reported being on a DMD for more than five years. A majority of the participants
were on Interferon-β 1a and rest of the participants were on other types of DMDs. More than
half of the participants had experience with Interferon-β 1a and Glatiramer acetate during their
course of MS treatment. All participants who had some type of health insurance reported that
their insurance covered the DMD they were taking in part or fully. The three participants who
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were uninsured reported receiving their DMD through a drug support program from the
pharmaceutical companies making their respective DMDs.
Apart from DMDs, a majority of patients were also taking other medicines for symptoms
associated with MS. These symptoms included fatigue, headache, vision problems, neuropathy,
pain, sleep issues, overactive bladder, bowel problems, depression, cognitive problems, muscle
stiffness, muscle spasms etc. Participants indicated that they adopted non-pharmacologic
methods in order to better manage their MS and associated symptoms. Such methods included
physical therapy, prayers, water therapy, meditation, and relaxation activities such as fishing
and sitting with pets. Participants also reported to make dietary changes by cutting out on
foods containing gluten, dairy products, eggs, products containing yeast, etc or by drinking Noni
juice. A few participants also reported using herbals (St. John’s Wort) and supplements
(Vitamin D, Vitamin B12, etc).
The following five themes were identified from analysis of the transcripts: 1) positive
experiences of DMDs, 2) negative experiences of DMDs, 3) DMD adherence, 4) perceived or
actual value of DMD, and 5) expectations from future DMD.

Theme 1: Positive experiences of DMDs
Positive experiences were related to patients’ perceived improvements in their quality
of life, mainly related to energy levels, cognition, and a general feeling of well being.
QOL/General wellbeing
P1N1 “I had no problems on my drug. You know it’s just worked out well for me. So my quality
of life is good.”
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P1N2 “Starting on it (DMD) I was able to gain my weight back and a little bit extra and my
quality of life is fantastic. I mean for what it was and what it is I really can’t complain.”
P2N4 “I think it helps me to keep from feeling worse.”
P3N6 “I don’t want to move back in hospital and so that’s why I do take them.”
Energy Levels
P3N3 “I take it regularly. I still got my energy levels the same I was.”
Cognition
P3N1 “Even my cognitive skills, I think clear my, brain’s not fuzzy.”
Relapse Reduction
Patients highlighted the fact that they were experiencing less relapses which added
significantly to their positive experiences with DMDs.
P1N1 “I have had fewer relapse so I feel that it (the drug) is doing its job then.”
P3N2 “I believe mine is (working) because I have not had a relapse but only once, and my hope
is that it continues to work.”
P3N4 “I take my treatments knowing that is not a cure but hopefully it will prolong the time
between the relapses because I know I can speak from my experiences you know, laying
in bed helpless, you know, you can look at your legs and your hands, want them to
move, and they won’t, they won’t listen to you. So if I can prolong that extra episode, I
will still take the treatments. The three years I am on it, I have not had a relapse.”
P4n2

“To have (relapses) just twice a year I would say that I feel that the medication I am on is
doing a pretty good job… If I have an injection site reaction, big deal. The overall results
are good, you know as long as I am upright and talking….”
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Theme 2: Negative experiences of DMDs
Negative experiences reported by patients with their current DMD or the ones that they
used in the past were associated with lack of treatment benefit, side effects, or concerns over
adverse events that were bothersome.
Lack of benefit
Some patients mentioned lack of benefits from their DMDs as they experienced
increased relapses leading to frequent hospitalizations, increase in the number of lesions on
MRI, or continued progression of their MS.
P2n2

“I don’t think it (DMD) helped me. My MRIs showed that I was getting worse.”

P2N3 “they (DMDs) were not working.. I was relapsing, relapsing, one after another, one after
another. I think when every time I was on the other drugs, I was in a hospital, getting
pumped with cortisone.”
P4N1 “I am not actually very happy with my drug, because I am just seeing steady decline. I
don’t really feel like that its helping me.”
Injection site reactions
Injection site reactions were commonly reported by the participants. Some injection site
reactions led to feelings of embarrassment and frustration.
P1n2

“When I take my shot, a lot of the time I will just get the redness but sometimes it will
swell up, it’s not as thick, it’s just a round cute lump. Being young you get vain and think
someone is looking at you because you have this huge tumor thing looking growing out
from wherever you took that shot.”

P2N2 “I had just local site reactions, the knots and the redness.”
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Side effects
Patients reported that side effects due to injection affected their day to day activities
and also affected their productivity for next few days. Patients also experienced other side
effects such as loss of weight, vomiting, flu-like symptoms, fatigue, chills etc. that made them
feel sick which they attributed directly to the injection they were on.
P1N2 “It made me really sick. And for some reason the day after I would take the shot it would
cause me to vomit. So, you just kind of knew the day after to be prepared. I lost a lot of
weight, I would say at least 15 lbs …..I got the flu like symptoms from it afterwards.”
P2N2 “if I take it the morning, I get puky sick so I take it at night and go to bed. ”
P2N4 “It was almost close to horrible, I would get chills, I would get fever… I do remember
couple of times just sitting with tons of blankets on me you know and every corner and
just shaking having so many chills”
P3N2 “zaps all the energy that you have…. It basically just sucks the life out of you for a day or
2/3 days”
P3N3 anything more or less that is inconvenient for me is the headache”
P3N5 “I seem to have little less energy compared to other ones”
P3N6 “the night I take my injections, next day I will do nothing. I usually get real sick and cold
chills. I will get hot. I will get up and sit in bath tub all night running under the hot
water. The day after (I take my DMD) I am braindead”
P4n1

“I make sure to take it later in the day so if I do have any flu like symptoms or any like
feeling just bad from it, I sleep through it”
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Certain side effects related to the DMDs that did not subside with the passage of time or
made patients feel worse about their condition were more concerning. Those were some of
the main reasons behind switching DMDs. While choosing a DMD one patient said that he
traded off between frequency and the perceived level of side effects keeping benefits as
constant thinking all DMDs deliver same level of effectiveness.
P1N4 “When I was trying to decide what treatment to go on, I chose it because it was the least
symptoms and they don’t have to do the blood work or check your liver function. Even
though its once day but it was really convenient I just felt that it might be the safer one
for me to try since all I mean that outcome of all them is about the same.”
P3n5

(About Past DMD1) “the reason I switched with it was I would have adverse reaction,
every time almost, I would get the shot, it felt that if you took a pin and prick my face, it
would just explode. I just felt like all the blood, my body was pushing into my head, and
like I said the last time I took it, I passed out. Just to give the story I was sicker than a
dog”
(About Past DMD2) “I felt like I had full blown flu and then next 3-4 days I am slowly
recovering from that and then I have to take my shot again. So it’s just the same thing
over and over again, and it just started to get really repetitious”
Patients voiced their concern that DMDs might affect their organ like, kidney, liver,

heart, etc. Side effects of DMDs which made patients feel worse about their condition made
patients think whether it is because DMDs are affecting the organs. Despite getting routinely
tested for enzyme levels and finding it to be normal, patients had a constant fear at the back of
their mind.
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P1N1 “After I was on it like 3 months where my chest tightened up real bad and I was like I felt
like I was going to fall right over and I felt I was having heart attack.”
P1n2

“since I was getting sick so much, I was much concerned about it damaging the liver or
kidney it would affect but as long as I was having the blood work done and it came up
fine I was okay with that, but there still always that thought at the back of your mind
thinking well, is it damaging a little at a time by the time they catch it its going be too
late”

P2N2 “I know it lowers my white blood count, so I can’t be around sick people. I am a nurse
that makes it hard. I have two kids so that makes it hard.”
P3n2

“Is it going kill my liver, you know, or is it going to affect any other organs in my body,
my kidneys….. am I going to develop congestive heart failure from this modifying drug
later on in my life as I get older.”

P4N1 “I am somewhat concerned about what it’s doing to the liver”
P4N2 “I will have real rapid heart rate and I will get red, just red as in cherry red. I feel like I
never had a heart attack before but it sure do feel pretty close.”
Theme 3: DMD adherence
Positive aspects affecting adherence
Adherence with DMD among MS patients was found to be the function of, mainly,
convenience aspects of a DMD and the belief that it helps them maintain day to day activities.
Although some DMDs may cause a feeling of weakness, patients were willing to tolerate it as a
trade off for being able to stay mobile. Being able to enjoy life with family and kids and
maintain independence of physical functioning is what made patients take their DMDs as
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prescribed. Patients displayed an understanding that there is no cure for their MS and taking
the DMD is the only hope that is going to keep the disease progression at bay and keep them to
remain healthier and mobile for a longer period.
P2N2 “I take mine as prescribed because my goal is to stay mobile as long as I can, to stay out
of the wheelchair”
P3N2 “My thought process was, take it once a week for one day, for one day harpooned for
one day and get through it, and you got six days to do what you can.”
P3N3 “I don’t want to progress and get worse…I don’t want the thought of someone happen
to dress me, feed me…. one (another reason) is my children, I want to be able to get out
and walk and do simple things… course and my wife, she is really adamant but that’s
why I take my medicine and I take it as I am supposed to.”
P3N4 “My energy levels might be low now, but at least I am not laid up in bed”. So I haven’t
missed any of my therapy treatments at all”
P4N2 “I want to stay as healthy as I can, and if I take my DMD, it is helping me, so I am not
going to mess that up. I can’t beat the MS, but I can control it. So if taking this medicine
helps me I am on that bus. I am not going to miss it.”
Some patients understood that injection site reaction is part of DMDs and were willing
to bear with the injection site reactions as long as the treatment was working for them.
P4n3

“I have accepted it. I mean you know I go with it. I just figured as long as its working I
will tolerate some red spots and knots.”
Convenience, frequency, and flexibility of administration of DMDs were associated with

adherence. There appeared to be a higher preference for not having to self-inject the DMDs
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and having to take the DMD less frequently. It was more convenient for some patients to take
their DMDs in their own home.
P2N2 “I would take my shots on my own, not though that it was convenient to take everyday,
and my pills are very convenient to take everyday”
P3N2 “It is convenient to take it in my own home.”
P3N5 “since I have been on it (DMD), I love it, because you know, the ease of it, not having to
self administer, you know, you just go to the doctor once a month and then it’s done for
the next month before you have to go back to have another infusion”
P3N6 “It’s pretty convenient only having to take just once a week”
Negative aspects affecting adherence
Whereas, one patient mentioned that the major inconvenience for her was to travel
long distance to get her monthly infusion. It was an important issue for her due to her inability
to drive as a result of MS related disability and that she needed to find someone to accompany
her to the clinic. However, this inconvenience was balanced off by the convenience of monthly
frequency of DMD.
P4N1 “I had to go to Pittsburgh to get the shot so that was like 55 miles away and it was, it
would have been more convenient if I could have gotten the infusion somewhere in the
Uniontown, but it’s nice that you can go one time and get it done with it”
Some talked about their inability to self-inject and the need to seek help from others to
get injections. In such situations, it was hard to find a person who would inject appropriately.
Other issues that were brought up were simply forgetting to take their DMD, running out of
medicine while being away from home, and being in a place where it’s not convenient to take
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it. Self injecting can be inconvenient to the patients who have disability or aggravated
symptoms of MS. It is recommended that the injection site should be rotated periodically in
order to allow for a recovery at the injection site and to help to decrease the chances of
injection site reactions. However help is required in order to take the shot where patient
cannot reach. Patients reported having somebody to give them the injection was very
convenient.
P1N2 “I do take it a lot in my stomach. I have a hard time in the back side area because you
can reach only so far. I have tried to have my fiancé to try help me and he is deathly
afraid so it’s all by myself”
P1N5 “If you can get somebody to help yourself, (but) it’s hard. If you can find somebody to
give you a shot, right there is one (pointing towards his Fiancé’). She got scared to
death, you could ask (her)”
P2N3 “I can’t reach my shots; my sister gives it to me.”
P3N2 “if wasn’t for my wife then, you know, be there to help me because I can’t do that
myself”
P3N3 “I have been a bad girl and run out of medicine, or forgot to take or been away at camp
and didn’t take enough medicine with me”
P3n4

“I am not needle shy, I am not stick shy. Now after couple of years of poking myself,
yeah I got a nurse to do it for me made it easier.”

P4N1 “I was self injecting myself. Now my hands I have tremors, so people say you should try
it. So I actually have somebody coming in and doing it for me.”
P4N2 “I rotate the injection sites. My husband does all of them but my stomach, and I do my
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stomach”
P4n3

“Yeah I pretty much take it, there may be a time or two that I miss because of
appointment or something or I am not in place where I can do it but other than that I
take it. Three times a week, every time same time all of that.”
Those who reported that they do not take their DMDs as prescribed reported following

reasons for their non-adherence. Some patients reported needle phobia while some patients
simply didn’t like the ritual of getting stuck with the needle every now and then.
P1N1 “that took little more courage to jab that needle down in my leg”
P1N2 “It’s a hassle to have to take it every day. I know that I should, but I guess since I am
young I have the mind frame that I am invincible…. I believe if you try to think positively
it’s going to help you… it’s such a low dose that it’s … I kind of rationalize thinking if I
skip a day, it will be okay.”
P3N2 “I don’t look forward to you know getting stuck with the needle, I mean I am not a
chicken but you know if I can’t get away from it, then I will take it.”
P3n5

“I never missed it (DMD), but I wish I would have some time, because I dreaded the shots
so much that, you know, I wish I should have missed some days.”

P3N6 “I don’t like needles. I am a big baby I don’t like shots, but I have been taking them.”
Theme 4: Perceived or actual value of DMD
Patients provided valuation of DMDs using monetary value and effectiveness of the
treatment.
Monetary Valuation
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For one patient cost was a factor that prompted him to split his doses for out-of-pocket
costs reasons. Splitting doses can affect treatment outcomes. One patient didn’t have any type
of insurance and found it hard to pay for the DMDs and had to go without any treatment until
he had the insurance that covered his DMD costs. A majority of the patients were aware of the
reported cost of DMDs without insurance. Many were concerned about affordability of DMDs
in case they lose their health insurance in the future or the Insurance stopped covering their
DMD for any reason.
P1n1

“I pay copay, if the insurance didn’t pay for it I wouldn’t be on it, because there is no way
to pay for all this.”

P1N4 “For a period of time where I only took one shot every other day because of my
insurance, and I had to pay for the whole amount one month’s supply myself so I took it
every other day instead of every day… to spread it out for two months. Then beginning
of next year my insurance picked back-up….“
P1n2

“It doesn’t matter how much money you make, there is no way you could physically pay
that much money a month that’s just not possible but my insurance pays a lot so I am
not concerned about paying for it but it’s always a scary though at back of your mind
that for some reason you lost it then there it’s just not possible to continue taking it.”

P3N1 “without the insurance there is no way I could afford that”
P3N2 “I don’t pay it for personally but if I didn’t have insurance, I couldn’t afford it. My copay
is $50 a month my insurance pays the rest of it. And of course that being said one day
the insurance company may call and say look we will pay this but you are going to pay
more for that.”
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P3N4 “without my insurance I would be dead fast, so that to me is a major concern”
P3n5

“I couldn’t get the medicines, I didn’t have the money”

P3N6 “I had no trouble other than paying to take it”
P4N3 “if they (insurance) stopped covering it, yeah I couldn’t take it because it is just too
expensive”
High premium for the DMDs was also a concern for patients who were on private plans.
P1N4 “I have to keep paying high premium, so, my concern is the premiums you have to pay”
P1N5 “I had a big issue with how I am going to pay for and everything”
Patients who did not have any insurance or those whose insurance did not cover DMDs
sought to receive DMDs through support programs of Pharmaceutical companies. Those
patients expressed their gratitude for receiving DMDs.
P3n5

“I am on the support program, thank the lord, they provide the medicine to me, for the
month and the only thing that I am required to pay for is the administration itself”

P4N1 “I mean if they (Pharmaceutical company) wouldn’t have helped me I wouldn’t be taking
the medication because I couldn’t afford.”
Benefit Valuation
Patients valued perceived effectiveness of DMDs in general and believed that taking
DMD help them in preventing relapses, maintaining their mobility and vision, and have a better
quality of life.
P1N2 “I believe that taking the shots will prevent relapses which will keep me mobile so as
long as I take my shots like I am supposed to. Continuing to receive treatment will keep
me walking, being able to see, etc”
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P2N3 “I think if I stop taking it, I think maybe I would run into problem. I thought about not
taking my drugs just to see what I would be like, but I don’t think I can do it, because I
think I will be worse”
P3n2

“there is no cure, but there are treatments, they are better now and you can live a
wonderful life enjoying”

P3n3

“the reason more or less I stay with the medicine. I don’t want to be dependant yet.”

P4N3 “I think the medication keeps me doing the things. I can’t do everything like I did before
but what I think is that it (DMD) helps me do that, because without it I don’t think I will
be able to do anything”
Side Effect Valuation
Some patients selected their DMDs with more frequent injections administration over
DMDs with less frequent administrations because they didn’t want worry about periodic tests
to test if there was any issue with liver due to the DMD. Few patients were interested in trying
monthly DMD, however, their concern was the chances of adverse event associated with it.
However, patients mentioned that they would like to see more data and saw more value in the
monthly frequency of administration.
P3n2

“such severe side effects (PML)is a little bit scary so I would like for them to do little
more research about that, or what could do about it but cause that was the once a
month infusion that would be incredible that you don’t have to take shots.”

P4n2

“The reason that I picked my DMD because I didn’t want to have to go and have my liver
checked, and I wanted the best thing that I thought. And the worst thing about it (DMD)
is I have to take it every day. That’s a big deal. That versus going to get my labs done all
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the time.”
Perceived Cost of Lost Opportunity
One patient who chose not to start using DMDs soon after getting a diagnosis of MS
expressed her regret that she should have started taking a DMD soon after diagnosis in order to
avoid disability.
P3n1

“I also didn’t start the treatment right away. That might have been a bad thing too”

Diminishing Utility
There was a false impression with respect to DMDs which revealed that a patient
thought that it was okay to stop treatment with DMD after a certain age as it does not help
after a certain point.
P3n1

“In the beginning I went to support groups and I had a networking of friends and
acquaintances on different drugs and therapies and everyone of them told me, that
when you hit 50 you don’t have to take the stuff anymore, you can stop.”

Theme 5: Expectations from future DMD
Pills
Although a majority patients reported overall satisfaction with DMDs they were
currently taking, many hoped that the future DMDs would be available in easy to administer
formulation such as an oral dosage form.
P1n1

“I would like us to have as a pill instead of a shot. Even though I take my shots with no
problems.”

P1n3

“I would just love to take a pill.”

P1n4

“It would be better I think if they could just give you an IV and (it will) last (for) an year.
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Take an IV one day and you are good for an year.”
Some felt that having DMD in pill form would improve adherence.
P1n5

“I agree too, because it would be easier to take, and if you take a pill you will not skip it.
You will take it.”

Repair myelin
Some patients had high expectations from DMDs such as to providing a cure by
repairing damaged myelin.
P1N2 “It would be nice if for some reason you having multiple relapses, its causing so much
damage so I mean I will have to agree if there was a pill, shot, a liquid, anything that you
could take to help repair the damage that will be phenomenal.”
P1N4 “I wish they could find the way to repair the myelin that’s damaged and causing the
nerve not to work right.”
P4n1

“I am actually not really concerned about the DMDs as much as I am looking for
something that will repair myelin.”

Improvement in health
Some patients expect their current DMDs to work in the long term by allowing patients
to remain in a stable condition without progressing to a worse condition. They also expected
that DMDs would help in regaining strength and mobility.
P2n3

“I am hoping that this treatment that I am taking will last for a long time. In other
words, I hope down the road, 10 years from now, I feel like I do now. I am hoping the
legs will get stronger, and I won’t need a cane or I don’t need a walker”
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Cure
Patients were well aware of the fact that currently available DMDs can only reduce the
relapse rate and delay the worsening of MS. They expected future MS treatments should cure
the condition instead of slowing the course of disease.
P3n2

“Unless that serves a complete cure for this disease, my expectations are not high.”

P3N5 “Until you call me and say I got a cure for it I don’t really care.”
Better than current DMD
One patient expected that the newer DMDs worked better than her existing DMD.
Newer DMDs were not an option for her until they were in the market for a while and used in
larger population to make sure there are no concerns associated with it.
P4n3

“But I am kind of the theory and the position now that if it’s not broken so don’t fix it. If I
would stop taking it (current DMD) and take something else, would I do as well? So
that’s… it (current DMD) works, so stay put. I bet new drugs come out. They have got to
be around and I got to see the results and know, because I am asthmatic and I have
other problems that I have, so I don’t want to create other problems with what I already
have. So I need to make sure it works.”

Despair
Some patients did not have high expectations from the future DMDs.
P3n4

“I have no expectations. There is no need to get your hopes up”

P4n2

“I know in the real world it will be wonderful if they could come up with the cure and no
one would have to go through what we go through. But I know that will never be a
possibility.”
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Discussion
To the authors’ knowledge, this is the first study to utilize qualitative methods to
understand DMD experiences and expectations among MS patients. Using qualitative methods
allowed the researchers to understand the broad range of perspectives among patients who
had the experience of using one or more DMDs to treat their MS. There was an overall
understanding among patients that currently available DMDs used to treat MS are capable of
preventing relapse rates more or less to the same extent, and there is no cure available for MS.
A majority of patients believed that the DMDs to be effective in preventing their relapses and
progression of the disease. Reduction in frequency of relapse was the most important
perceived benefit that patients experienced with their DMDs. Other perceived benefits
experienced by patients were related to their general sense of well being, ability to stay mobile,
be physically active, maintain cognitive health, and experience high energy levels. Relapse rate
reduction is one of the most important clinical outcome measures used to determine efficacy of
DMDs in clinical trials and clinical practice. Health related quality of life (Using Multiple
Sclerosis Impact Scale-29), ability to stay mobile (Expanded Disability Status Scale/Patient
Determined Disability Steps), physical activity (Short Form-36/Short Form-12), cognitive health
(several cognitive function batteries), and energy levels (Modified Fatigue Impact Scale) are also
used routinely in clinical trials, health outcomes studies, and clinical practice. MS affects
different aspects of patients’ life; hence, the impact of MS on patients is often
multidimensional.
Negative experiences with DMDs were related to perceived or experienced lack of
efficacy, injection site reactions, and side effects. Patients thought that DMDs just provide a
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security blanket as chances of relapse rate reduction is more or less the same with all the
DMDs. Injection site reactions are quite common among patients taking parenteral DMDs.
Many patients in our study experienced injection site reactions with their DMDs.
Discontinuation or switching of DMDs among patients in this study was mainly due to injection
site reactions and side effects of DMDs. Although the study participants had not experienced
any major adverse event due to their DMDs, they shared their concerns about chances of
adverse events associated with DMDs in general.
Adherence with DMDs among MS patients is a major issue. A recent systematic review
by Giovannoni (2012) indicated that the average rate for DMD discontinuation ranged between
16% and 27%. Previous studies evaluating adherence and factors influencing adherence to
DMDs among MS patients have indicated that a significant number of patients stop taking their
DMDs within the first six months after starting therapy (Mohr, 1996; Tremlett, 2003). Higher
discontinuation rates for first line DMDs were observed in other long term follow up studies
(Rio, 2005; Portaccio, 2008). In this study, the following factors appeared to be associated with
adherence: perceived/actual benefit of delaying disability, convenience of administration,
frequency of administration, flexibility of administration, perceived quality of life, ability to selfinject, finding help to give injections, forgetting to take it, insurance coverage, not having
enough medicine, etc. These findings were consistent with previously published studies
(Treadaway, 2009).
A majority of patients in our study had health insurance which covered their DMD and
the patients were only responsible for the co-pay amount. Those who did not have any health
insurance were receiving their DMDs through support programs. Almost all patients were of
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the opinion that it would be impossible for them to take their DMDs if their insurance did not
cover the drug. Prescription coverage for the DMD and adherence were also found to be
related. The out-of-pocket costs were of minimal concern for the patients in this study. Other
studies have found that with the increasing out-of-pocket costs, the abandonment rates go up
(Gleason, 2009). The data also suggests that apart from the monetary valuation, patients
constructed value of DMD from the perceived clinical benefit, quality of life, and severe adverse
events. It was interesting to know patient valuation of DMDs based on perceived cost of
missed opportunity to initiate treatment with DMD after initial diagnosis. Another interesting
valuation of DMDs was a perceived diminishing benefit from DMDs.
Although there are different DMD options available for MS patients, the chances of
relapse reductions are fairly similar 30% (Goodin, 2002) and the effectiveness of these DMDs
also depend on patient and disease related factors. Currently available DMDs are all injections
except one, which is an oral formulation. Acceptability and adherence are always concerns
with these treatments. The safety profile of some of newer injectable and oral DMDs is not as
favorable as their effectiveness. In our study, patients hoped to see newer DMDs with better
mechanisms of action (myelin repair), routes of administration (oral), quality of life, and
something that could potentially cure them.
The following limitations should be noted. First, the patients participating in this study
were associated with a single clinic affiliated with a teaching hospital. Patients who
participated were identified by self-selection, and may not represent other MS patients
attending the same clinic. Moreover patients were residents of the Appalachian region. The
MS Patient populations from other clinics or geographical areas may have had different
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experiences, opinions, and expectations. A multicenter study involving a larger sample of MS
patients could overcome this limitation and provide richer data on patients’ experiences,
opinions, and expectations. Another limitation is that it is possible that some patients might not
have shared negative thoughts about their treatments due to inhibitions although the
moderator addressed confidentiality before starting the focus group process. In addition, the
moderator disclosed to participants prior to starting focus group discussion that he was not
involved in their clinical care which may have affected their responses. Including only those
patients who were taking DMDs at the time of participation may have contributed to selection
bias. Patients who have discontinued their treatment with DMDs, patients who are newly
diagnosed, or those who never took DMDs to treat their MS may have different treatment
experiences and expectations.
Conclusion
Several DMDs for the treatment of MS have shown promising results in phase 3or late
stages of drug development. Treatment options for MS patients are expected to increase
significantly in the near future. The toxicity profiles of all the new treatments may not be
completely known. A possibility of higher risk with treatments with high efficacy and easier
routes of administration cannot be ruled out as these drugs would be relatively new and would
lack long term safety-efficacy data. This study shows qualitative evaluation of experiences with
existing DMDs and expectations of future DMDs from MS patients’ perspectives. With
continuous improvement in the diagnosis criteria, it is now possible to have early diagnosis of
MS. The current outlook on therapeutic management of MS supports early initiation of DMDs
in order to achieve optimal clinical outcomes in the long-term. It is possible that patients’
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preferences for benefit risk might differ from that of clinicians. Hence, with the increasing
number of treatment choices, MS patients’ involvement in complex treatment decisions will
become even more crucial. In order to select the best possible treatment for an individual MS
patient, it is imperative to choose a treatment that is clinically effective, while keeping their
preferences and needs in mind. Improving patients’ knowledge about benefits and risks of
DMDs and allowing them to actively participate and make informed treatment decisions will be
increasingly important and challenging with respect to future treatment.
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Table 2.1: Currently available DMDs for treatment of multiple sclerosis
Drug
Interferon-β-1a

Brand Name
Avonex® Biogen

Route
IM

Frequency
Once a week

Interferon-β-1a

Rebif® EMD Serono & Pfizer

SC

Thrice a week

SC

Every other day

SC

Once a day
Once a day
Once a day
Once every three months
Once every 4 weeks

Interferon-β-1b
Interferon-β-1b

®

Extavia Novartis
®

Betaseron Bayer
Gilenya® Novartis

Fingolimod
Glatirimer acetate
Mitoxantrone

Copaxone Teva
Novantrone® EMD Serono

Oral
SC
IV

Natalizumab

Tysabri® Biogen

IV

®

IM – Intramuscular Injection
SC – Subcutaneous Injection
IV – Intravenous Infusion
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Table 2.2: Sociodemographic information of focus group participants (N=18)
Sociodemographic Variable

Subjects, n (%)

Sex
Male
Female

7 (39)
11 (61)

Marital status

Age

Single
Married
Divorced or Separated
Years (Mean ±SD)
(Range in years)

4 (22)
12 (67)
2 (11)
48.50 (±14.43)
26-70

Race
White/Caucasian

18 (100)

Education
Some high school or less
High school graduate or GED
Vocational College or some college
College degree
Graduate/ professional degree

1 (6)
5 (28)
6 (33)
4 (22)
2 (11)

Insurance
Private health insurance
Government health insurance
(Medicare/Medicaid)
Uninsured
Employment status
Employed/self-employed full time
Retired
Homemaker
Unable to work due to MS
Household income
<$25,000
$25,000 - $49,999
$50,000 - $99,999
Refuse to answer
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5 (28)
10 (55)
3 (17)
4 (22)
4 (22)
1 (6)
9 (50)
5 (28)
7 (38)
5 (28)
1 (6)

Table 2.3: Multiple sclerosis history and treatment information of focus group participants
(N=18)
MS related Variable

Subjects, n (%)

Time since diagnosis of MS
< 5 years
5-10 years
>10 years
Primary diagnosis
Primary progressive
Secondary progressive
Relapsing remitting
Progressive relapsing
Don’t know
Time since initiation of DMD
≤ 5 years
>5 years
Current DMD
Avonex
Rebif
Betaserone
Copaxone
Tysabri
Drug in a clinical trial
Past use of the following DMD*
Avonex
Rebif
Betaserone
Copaxone
Novantrone
Tysabri
Drug in a clinical trial
Prescription drug coverage
Yes
No

5 (28)
5 (28)
8 (44)
2 (11)
1 (6)
12 (67)
1 (6)
2 (11)
8 (44)
10 (55)
5 (28)
4 (22)
1 (6)
5 (28)
2 (11)
1 (6)
9 (50)
6 (33)
2 (11)
10 (55)
1 (6)
3 (17)
1 (6)
15 (83)
3 (17)

*- Responses not exclusively limited to one DMD hence the percentage will not add to 100%
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CHAPTER 3

BENEFIT-RISK PREFERENCES FOR DISEASE MODIFYING TREATMENT AMONG MULTIPLE
SCLEROSIS PATIENTS

Abstract
Objective: To use choice based, stated preference method to estimate preference weights and
relative importance of attributes for disease modifying drugs (DMDs) used in the treatment of
multiple sclerosis (MS).
Methods: A total of 3,743 individuals with MS who resided in the US were invited to participate
in an online survey. These individuals were part of an MS registry and an online medication
monitoring service provider in the United States (US). The survey questionnaire included nine
choice-based conjoint tasks. Each task involved two hypothetical DMD alternatives described
using seven attributes: treatment administration (mode), evidence on treatment outcomes in
years (evidence on outcomes), number of relapses within 5 years (relapses), delaying disability
progression by ‘n’ years (delaying disability progression), severe disability or death from
progressive multifocal leukoencephalopathy (PML) within 5 years, severe liver dysfunction
within 5 years (liver dysfunction), and experiencing flu-like symptoms following DMD
administration (flu-like symptoms). Each attribute had 3 levels. Relative importance of DMD
attributes and attribute levels were estimated using c-logit regression model. Parameter
estimates of all attribute levels were rescaled in the range of 0 to 10 and grouped by attribute.

67

Results: A total of 897 individuals completed the survey (~24% Response rate). PML was the
most important attribute followed by liver dysfunction, flu-like symptoms, delaying disability
progression, relapses, and mode of DMD administration. Evidence on treatment outcomes in
years was the least important attribute to patients. The results of this study indicate a
preference for DMDs that have lower chances of severe adverse events (SAE) like PML and Liver
Dysfunction, and side effects affecting day to day functioning such as flu-like symptoms.
Participants also indicated a preference for lower relapse rate, delayed worsening of MS,
treatment in pill form, and stronger evidence on DMD outcomes in terms of number of years.
Conclusions: The results of this study indicate that efficacy and convenience of administration
are important factors in a DMD; however adverse events and side effects associated with DMDs
still continue to be the cause of concern for MS patients. The results show a need to address
patients’ concerns surrounding the adverse events to optimize selection of DMDs for MS
patients.

68

Introduction
MS is a neurological condition that typically affects young adults between 20-40 years of
age (Confavreux, 1980), precisely during the most active and productive period in their lives,
making it the leading cause of non traumatic disability in young adults (Dutta, 2007). Although
there is no cure for MS, advances in pathophysiological understanding of MS over the past two
decades have led to several therapeutic alternatives, commonly known as disease modifying
drugs (DMD). National Multiple Sclerosis Society recommends initiation of DMDs in patients
soon after they are diagnosed with MS. Seven DMDs are currently approved by the United
States Food and Drug Administration (US FDA) for the treatment of MS. Six of these DMDs are
available as injection and only one DMD is available in oral form. Primary goal of available
DMDs is to reduce relapse rate and to delay progression of MS (Montalban, 2007). Several
promising therapies are currently being studied in late phase clinical trials. In future, DMDs
with different mechanisms of action, formulations, modes of administration, and frequencies of
administration are expected to foray in the market resulting in an increase in the choice of
DMDs for patients and clinicians.
Therapeutic decisions in MS can be challenging due to the inconvenience of
administration, frequency of administration, longer duration of therapy, and side effects
associated with DMDs. These factors can also contribute to reducing patients’ adherence with
DMDs. In order to make optimal therapeutic decisions with respect to DMDs, a better
understanding of DMD preferences among individuals with MS is required. A stated preference
method, such as conjoint analysis has been increasingly utilized to elicit patients’ preferences
for health care interventions and treatment outcomes (Bridges, 2003; Bridges, 2012). As the
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DMD options are increasing, involvement of MS patients will be ever more vital in therapeutic
decision making and the success of it thereof. With the growth of evidence based health care,
understanding what patients prefer in their treatments would not only improve patient care
but also aid in achieving the best possible treatment outcomes. Although patient preferences
have been studied for a range of therapies for various health conditions, only one published
study evaluated benefit-risk preferences for DMDs in patients diagnosed with MS (Johnson,
2009). This study utilized attributes associated with DMD efficacy and mortality risk. However,
patients may define DMDs using attributes additional to those used in a previous study. The
attributes of DMD used in the treatment of MS included in this study were developed using
rigorous qualitative interviews with MS patients reflecting attributes used by them to evaluate
DMDs.
The purpose of this study was to use a choice based, stated preference method to
estimate preference weights and relative importance of attributes for DMDs used in the
treatment of MS.

Methods
Conjoint analysis is a method based on the assumption that any product, service, or
intervention can be defined by its attributes and the value of such product, service, or
intervention for an individual depends on the level of its attributes (Ryan, 2000). Conjoint
analysis is a valid, reliable, and commonly used technique in evaluating attributes that are
preferred by patients in their treatments along with the magnitude of each attribute that
influenced their preferences (Ryan, 1997; Johnson, 2007). In conjoint analysis, preference by
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patients assigned weights to different treatment attributes are quantified by asking patients to
choose between 2 or more treatment choices where treatment options are varied by the levels
of predefined treatment attributes (Bridges, 2007; Bridges, 2003; Johnson, 2010). Conjoint
analysis has its roots in mathematical psychology and economics (McFadden, 1973; Anderson,
1977), and is commonly used in market research (Green, 1978; Green, 1990), transport
economics (Louviere, 1988), environmental economics (Ch.Gan, 1993), healthcare services
(Ryan, 2000), and medicine (Bridges, 2008). Our study was guided by good research practices
laid out by the ISPOR Conjoint Analysis Task Force (Bridges, 2010).
Survey Development
Salient features of DMDs used in the treatment of MS were identified using focus group
discussion with MS patients, literature review, and consulting with neurologists and neurology
research nurses treating MS patients. Four focus group discussion sessions involving a total of
18 individuals with self-reported clinician confirmed diagnosed of MS were conducted. All
patients had experience of using DMDs to treat their MS. Focus group discussions were audio
recorded and transcribed. Transcripts were analyzed by 2 blinded reviewers to identify DMD
attributes and respective levels. The neurologist and neurology research nurse treating MS
patients were consulted prior to the final selection of attributes and their levels. Seven DMD
attributes with three levels each were used in the survey (Table 3.1). Two attributes were
related to DMD benefit (reduction in the number of relapses in the next 5 years and delay in
the progression of MS), three attributes were related to risks associated with DMDs (severe
disability or death from PML, severe liver dysfunction, and flu-like symptoms), mode of DMD
administration, and evidence on outcomes in terms number of years of research.
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A brief description of measures of outcomes (attributes) and objective of choice
questions were provided to all patients for them to better improve comprehension of choice
tasks. The initial version of the web based survey was pretested using in-person, open ended
interviews. The objective of pretesting the survey questionnaire was to determine cognitive and
time burden. Seven patients with MS between 24–60 years of age participated. All
participants had a clinician diagnosed MS, current use of DMD, and relapse-free at the time of
pretesting. Patients in the pretesting phase reported that they understood the explanation
tasks completely and accepted trade-off among DMD attributes. Understanding of meaning of
attributes (benefit/risks) with respect to DMDs, time taken to complete the survey,
ease/difficulty in understanding meaning of terms, font, colors, etc were also evaluated.
Information gathered during the pretest was utilized to make small changes related to number
of words, ordering of questions, font size, and questions per screen in the web based survey.
In the final web-based survey, each task had 2 treatment choices with varying levels of
attributes. An example of a choice task is shown in Figure 3.1. Using seven attributes
mentioned above with three levels each, 2,187 unique treatment profiles were generated.
Using 2,187 profiles one could create approximately 2.4 million different pairs. A D-optimal
experimental design which consisted of 81 choice pairs was generated. Minimal overlap in the
levels of attributes was allowed in order to avoid lexicographic responses by patients. The
design met the criteria for level balance, orthogonality, and utility balance (Ryan, 2008). In
order to reduce cognitive and response burden, these pairs were divided into 9 blocks
comprising of 9 choice tasks per block. Each patient randomly received 1 out of 9 blocks. One
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choice task from any given block was repeated at the end of 9th choice task which was used for
the purpose of response validation (Johnson, 2009).
Survey Respondents
The web-based survey was developed using Qualtrics survey software. Patients
diagnosed with MS were recruited using two separate panels of MS patients in the US. Details
of survey participants are provided in Figure 3.2. The first panel comprised of MS patients who
are subscribers of www.MediGuard.org, which is a free medication monitoring service that
provides patients with safety alerts, recalls, a check for drug interactions, and other drug
related updates. The second panel was comprised of MS patients from the Biogen Idec Mailing
list. Participants were required to be 18 years of age or older, have a self reported clinician
confirmed diagnosis of MS, and have current residence in the United States. Web-based survey
was administered from August 2011 through November 2011. All participants completing the
survey received a $25 gift card as an incentive for their participation. Apart from conjoint
analysis choice tasks, all patients were asked to provide information on sociodemographic
characteristics, patients’ experiences with multiple sclerosis, treatment history, health status,
health related quality of life, and satisfaction with current treatment. This study was approved
by the West Virginia University Institutional Review Board. Out of 971 patients who completed
the survey, 897 passed the data validity checks.
Statistical Analysis
We estimated preference weights for each level of attribute using c-logit regression.
Dependant variable in the regression model was the preferred treatment profile from the
choice tasks whereas the Independent variables in the c-logit regression model included
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attribute levels given in table 3.1. Each attribute had three levels, and rather than dummy
coding attribute levels where one level would be used as reference category, attribute levels
were effect coded in order to allow parameter estimation for all attribute levels. Effect coding
was done by excluding one attribute level and coding the remaining two levels as 1 in the
treatment profiles where that level was shown and the excluded category was coded as 0 if it
was not present in the treatment profile and -1 if it was present. In the effect coding, mean
effect for each attribute is represented by zero (Bridges, 2011; Johnson, 2010). The negative
sum of the parameter estimates that were included yields a parameter estimate for the
excluded attribute level (Hensher, 2005).
Relative importance weights were calculated for each attribute with reference to the
levels used for each of them. For example, relative Importance for an attribute (Number of
relapses within 5 years) was estimated as the difference in the probability of highest level (0
relapse within next 5 years) and the lowest level (6 relapses within next 5 years). Using the
same method, relative importance weights were calculated for other attribute. Importance
weights were converted for the most important attribute to 10 and the importance scores were
calculated for the remaining attributes relative to the most important attribute (Hauber,
2010b).

Results
Survey Population Characteristics
Email invitations were sent to a total of 3,743 subscribers in both panels. There were
1,097 individuals who accessed the survey. However, valid data for conjoint analysis was
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available for 897 respondents with a response rate of approximately 24% (Figure 3.2). A
summary of respondents’ sociodemographic characteristics is shown in table 3.2. A majority of
respondents were female (85%), living with the partner (61.2%), White (87%), post high school
education. The mean age of respondents was 50.51 years (SD 9.89). Nearly half of the
respondents reported an annual household income less than $50,000. A majority of the
participants were not employed out of which approximately 43% were not able to work due to
their MS. Respondents represented different regions throughout the US.
A summary of respondents’ multiple sclerosis and treatment related characteristics is
shown in table 3.3. The mean duration since the MS diagnosis was 11.48 years (SD=8.25). The
mean age at which respondents were diagnosed with MS was 39.04 years (SD 9.89). More than
half of respondents reported experiencing 6 or more symptoms associated with MS. The mean
total number of relapses experienced in the last 12 months by the patients was 1.40 (SD=2.01).
Patients were distributed across all disability levels. A majority of patients (73%) reported
current use of DMD for the treatment of their MS. Approximately 62% of the respondents
reported past use of DMDs.
Preference Weights
Differences in demographic and MS related characteristics of the respondents from
both panels were compared using chi square tests and analysis of variance (ANOVA) for
independent samples. Significant differences were found in all sociodemographic and MS
related characteristics, except in marital status and region. The parameter estimates for
attribute levels were compared to determine whether the preference weights were
significantly different across the two patient samples (Johnson, 2009). The data showed no
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difference in the preference weights of the two samples, hence we pooled the data from two
panels and aggregate results were used for interpretation.
Parameter estimates for all attribute levels are presented in table 3.4. Preference
weights showed a natural order of preference of levels confirming that patients comprehended
the differences in the three levels of any given attribute in the choice tasks. Patients indicated
their preferences for lower levels of severity for severe disability or death from PML within 5
years, severe liver dysfunction within 5 years, and flu-like symptoms (Figure 3.3). Preferences
for attribute levels associated with benefits suggested higher utility for larger gains in terms of
no relapse within the next 5 years and delaying progression of MS by 15 years (Figure 3.3).
With respect to mode of treatment administration, patients preferred pills over injection and
infusion, respectively. Patients also indicated a higher preference for treatments with stronger
evidence on outcomes where a treatment with 15 years of research was preferred over 10
years of research and 5 years of research, respectively.
Relative Importance
Relative importance scores for all treatment attributes are presented in Figure 3.4. Of
all the attributes included in this study, severe disability or death from PML within 5 years was
ranked as the most important attribute followed by severe liver dysfunction within 5 years and
within 5 years (relative importance score of 9.96). Remaining attributes were ranked in the
following order: flu-like symptoms (importance score of 7.11), delaying progression of MS
(importance score of 6.72), number of relapses within 5 years (importance score of 6.64),
treatment administration (importance score of 4.13), and evidence on outcomes (importance
score of 2.74).
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Internal Validity Tests
Choosing between hypothetical treatment profiles requires respondents to understand
the purpose of experiment. This ‘task’ can be challenging to comprehend for some
participants. Checking the quality of responses with respect to conjoint analysis data is an
important step, especially in the case of MS patients as there is a possibility of difficulty in
understanding the choice tasks, as MS could affect their cognition, limiting their ability to
comprehend complex tasks. However, out of the 971 individuals who completed the survey,
only 7.62% of the respondents did not pass the internal validity check. Seventy (7.20%)
respondents failed the stability test. Only 4 individuals were found to select either Treatment A
(or B) for all the 10 choice tasks.

Discussion
A majority of the currently approved DMDs for MS are used parenterally. Only one oral
DMD has been approved so far. All available DMDs have their own set of benefits and side
effects, other than differences in route and frequency of administration. The evidence on
safety and efficacy data also varies in terms of number of years.
In the last two decades there has been a marked increase in the emergence of various
DMDs for the treatment of MS. These agents help by reducing the relapses by about 30%
(Goodin, 2003). However, efficacy of these immunomodulatory agents varies depending on
several personal and MS related characteristics. Adherence and satisfaction with DMDs are
surrounded by the complexity in choosing a DMD and individual needs of MS patients to
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manage disease progression and symptoms related to their condition. Clinical and health
outcomes are associated with the use of DMDs.
Trade-offs observed between attributes in the patients’ responses to hypothetical
treatment choices implied that they understood the choice tasks. Patients made trade-offs
between benefits, risks, mode of administration, and evidence on outcomes (in years). Risk
attributes PML and liver failure were the most valued attributes, respectively. These two
attributes had almost equal weight in terms of relative importance. Flu-like symptoms
associated with DMDs are known to affect patient day to day activities following
administration. Relapse frequency and disability progression are routinely used as treatment
outcome measures in clinical trial and routine practice. Relapse rate reduction and delay in
disability progression had just about equal weights. Treatment administration had relatively
less effect on treatment preferences as compared to benefit and risk attributes. Patients
placed high value on oral DMDs compared to parenteral DMDs. Evidence on outcomes was the
least important attribute implying that although DMDs with stronger evidence were valued,
safety; efficacy, and route of administration were more important in selecting a DMD in given
hypothetical treatment choices.
Only one previous study evaluated MS patients’ benefit risk preferences in the context
of maximum acceptable risks (Johnson, 2009). In that study, five attributes were used to define
a DMD. Two efficacy attributes were used: reduction in the number of relapses in the next 5
years and delay (in years) to disability progression. Three were related to DMD risks: death or
severe disability from PML, death from liver failure, and death from leukemia. As per the
authors’ understanding, this is the second study to evaluate patient preferences for benefits
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and risks along with two key attributes, treatment administration and evidence on outcomes,
respectively associated with DMDs used in the MS treatment. The three attributes that were
not used in the previous study: Treatment administration, Evidence on outcome, and Flu-like
symptoms, respectively, were derived from the in-depth focus group discussions with MS
patients. Focus groups are a qualitative research method strongly recommended to generate
list of attributes for conjoint analysis (Coast, 2007).
Although conjoint analysis allows the study of patients’ valuation of treatment
attributes, this method has some limitations. One of the main limitations, is that patients are
asked to compare between treatment options that are hypothetical in nature. The treatment
choices do not have any the real life consequences. However, this limitation was overcome to a
certain extent by including treatment profiles that were realistic and clinically relevant (Hauber,
2010a). Patient preferences in conjoint analysis do not necessarily reflect real life decisions. In
this study, preference weights are estimated for aggregate data. Stratification of data based on
demographic or clinical factors might reveal different preference weights, which was beyond
the scope of this study. In conjoint analysis, it is expected that respondents pay attention to all
attributes and levels before selecting a treatment profile. It can be difficult to comprehend for
respondents under many circumstances (Bridges, 2003). Data quality tests (described above) in
our study were performed to overcome this limitation. The sample for this study was
subscribers from the two panels who self-reported a clinician confirmed diagnosis of MS. Four
regions in the US were represented in the sample. It is unknown if this is a representative
national sample of MS patients. The results of this study should be interpreted in the context
of attributes used to define DMDs used in MS.
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Conclusion
With one oral DMD for MS treatment already in the market, many more are anticipated
in the future. These oral therapies are going to provide much needed relief to MS patients and
clinicians, as far as ease of administration and adherence issues are concerned. However, just
as these oral therapies would provide certain benefits, the long-term efficacy and side effect
profile will not be fully known, as compared to the existing first line therapy. In this study,
although patients preferred oral mode of administration over parenteral, it was evident that
patients still place higher value on efficacy and safety attributes of DMDs. In the future,
eliciting physician’ benefit risk preferences for DMDs used in MS treatment would help in
comparing patient and physician DMD benefit risk preferences. Such information, in turn, can
be used to determine strategies to achieve medication concordance. Data from this study also
encourage the use of stated preference methods in routine practice, as well as in clinical trials
to better understand patients’ treatment preferences and to design better benefit risk
communication strategies.
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Table 3.1: Treatment attributes and levels
Attributes

Levels

1. Treatment administration

2. Evidence on outcomes

3. Number of relapses within 5 years

4. Progression of MS
5. Severe disability or death from PML
within 5 years
6. Severe liver dysfunction within 5 years

7. Flu-like symptoms
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Pills at home
Injection at home
Infusion at clinic
5 years of research
10 years of research
15 years of research
0 relapse
3 relapses
6 relapses
Delayed by 5 years
Delayed by 10 years
Delayed by 15 years
None
4 patients out of 1000
8 patients out of 1000
None
10 patients out of 1000
20 patients out of 1000
None
Mild
Severe

Table 3.2: Summary of participants’ sociodemographic characteristics
Sociodemographic Variable

n

Categories

Age (in years)

883

Gender

883

Marital Status

883

Race

884

Education

884

Income

883

Employment

884

Region

884

Range: 22-80
Female
Male
Without partner
With partner
White
Other
High school or less
Some college
Bachelor
Masters or above
<$25,000
$25,001-$50,000
$50,001-$75,000
$75,001-$100,000
>$100,000
Full time
Part time
Not Working
Unable to work due to MS
Northeast
Midwest
South
West
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Total Sample %/SD
50.51
751
132
343
540
769
115
145
365
262
112
226
253
202
112
90
238
97
168
381
197
227
289
171

9.89
85.1
14.9
38.8
61.2
87.0
13.0
16.4
41.3
29.6
12.7
25.6
28.7
22.9
12.7
10.2
26.9
11.0
19.0
43.1
22.3
25.7
32.7
19.3

Table 3.3: Summary of participants’ multiple sclerosis related characteristics
MS related Variable

n

Categories

Time since diagnosis of MS (in years)
Age at MS diagnosis (in years)

896
882

Total number of MS related symptoms

897

Number of relapses in past 12 months

893

Patient Determined Disability Status

897

Current DMD use

897

Past use of DMD

897

Range: <1-48
Range: 9-68
0 symptom
1-5 symptoms
6-10 symptoms
11-15 symptoms
16-20 symptoms
Normal
Mild Disability
Moderate Disability
Gait Disability
Early Cane
Late Cane
Bilateral Support
Wheelchair / Scooter
Bedridden
No
Yes
No
Yes
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Total
Sample
11.48
39.04
15
258
344
216
64
1.40
158
161
115
133
124
87
61
52
6
242
655
337
560

%/SD
8.25
9.89
1.7
28.8
38.4
24.1
7.1
2.02
17.6
17.9
12.8
14.8
13.8
9.7
6.8
5.8
>1.0
27.0
73.0
37.6
62.4

Table 3.4: Parameter estimates for disease modifying drug attributes
Attribute Name

Variable Name

Coefficient

SE

test-stat

Sig.

Treatment
administration

Pills at home
Injection at home
Infusion at clinic

0.311
-0.045
-0.266

0.026
0.024
0.025

12.120
-1.86
-10.475

***
0.063
***

Evidence on
outcomes (in Years)

5 Years of research
10 Years of research
15 Years of research

-0.233
0.082
0.151

0.026
0.025
0.026

-8.940
3.290
5.918

***
**
***

Number of relapses
within 5 years

0 Relapses
3 Relapses
6 Relapses

0.492
-0.056
-0.436

0.026
0.025
0.026

18.750
-2.250
-16.473

***
*
***

Delaying
progression of MS

5 Years of delay
10 Years of delay
15 Years of delay

-0.566
0.192
0.374

0.026
0.026
0.025

-21.520
7.410
14.682

***
***
***

0 out of 1000 patients
4 out of 1000 patients
8 out of 1000 patients

0.757
-0.116
-0.641

0.026
0.025
0.026

29.090
-4.670
-25.099

***
***
***

0.772
-0.151
-0.621

0.027
0.025
0.026

28.660
-6.030
-23.714

***
***
***

None
0.355
0.025
Mild
0.284
0.025
Severe
-0.639
0.026
*0.01≤p<0.05, **0.001≤p<0.01, ***p<0.001

14.070
11.350
-24.169

***
***
***

Severe disability or
death from PML
within 5 years

Severe liver
0 out of 1000 patients
dysfunction within 5
10 out of 1000 patients
years
20 out of 1000 patients
Flu-like symptoms
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Figure 3.1: Example of conjoint task
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Figure 3.2: Survey population
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Figure 3.3: Disease modifying drug preference weights for multiple sclerosis patients
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Figure 3.4: Relative importance of disease modifying drug attributes
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CHAPTER 4

ASSOCIATION OF DISEASE AND TREATMENT RELATED CHARACTERISTIC WITH TREATMENT
SATISFACTION AMONG INDIVIDUALS WITH MULTIPLE SCLEROSIS

Abstract
Objective: The aim of this study was to assess disease and treatment related factors associated
satisfaction with treatment among individuals with multiple sclerosis (MS)
Methods: Email invitations requesting participation in a cross sectional web-based survey were
sent to 3,743 individuals with MS. Individuals were affiliated with either an online medication
monitoring service provider or with a mailing list owned by pharmaceutical company in the
United States (US). Socio-demographic, MS related, and disease modifying drug (DMD) related
information was collected in the survey. Patient satisfaction with DMD was assessed using a
validated questionnaire - Treatment Satisfaction Questionnaire for Medication (TSQM) v.II, and
disability associated with MS was assessed using Patient Determined Disease Steps (PDDS)
scale. Sample differences between the two panels were evaluated. Associations between
patients’ socio-demographic, MS related, DMD related characteristics and the 3 TSQM domain
scores (Side effects, Effectiveness, and Convenience) and the Global satisfaction score were
analyzed. Multiple linear regression models were employed to determine MS and treatment
related factors that were associated with satisfaction with DMDs.
Results: A total of 951 respondents completed the survey questionnaire (response rate of
25.4%). Factors such as type of current DMD used, relapses, disability status, MS symptoms
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experienced, and past experiences with DMDS were found to have negative associations with
satisfaction scores. The overall satisfaction scores for individuals taking infusion (natalizumab)
DMD did not differ from those who were using oral (fingolimod) DMD.
Conclusions: The findings of this study reflect that the type of DMD and clinical factors are
associated with patient satisfaction among individuals with MS. Assessing treatment
satisfaction can help better understand MS patients’ value judgments with respect to their
experiences with DMDs.
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Introduction
Multiple sclerosis (MS) is a chronic demyelinating disease that affects the central
nervous systems and is characterized by relapses and remissions. The precise cause and cure
for this disease are currently not known. MS is known to be the most common reason behind
disability due to non-traumatic causes in young adults (Compston, 2002). The onset of MS
usually occurs among individuals 20-50 years of age, with the peak arising at 30 years of age,
when they are typically most productive (Compston, 2006; Zwibel, 2011), have a busy social
and family life, and financial commitments (Simmons, 2010). It has been known that acute
relapses result in significant worsening of disability in many individuals with MS and nearly half
do not experience complete recovery from it (Hirst, 2008). Disease modifying drugs (DMDs)
used in the therapeutic management of the MS are the mainstay therapies known to reduce
frequency of relapses thereby delaying worsening of MS and the resultant accumulation of the
disability.
Currently available first-line DMD therapy for MS includes interferon beta-1a,
interferon beta-1b, and glatiramer acetate and the second-line DMD therapy for MS includes
natalizumab, fingolimod, and mitoxantrone. Except fingolimod, which is the only oral DMD
available for MS, all other DMDs are delivered via parenteral mode of administration.
Interferon beta 1a, interferon beta 1b, and glatiramer acetate are considered to be relatively
safer but modestly efficacious (Goodin, 2002). Second-line DMDs exhibit significant efficacy in
active MS but are limited in their use due to adverse events associated with them (Rudick,
2011). Adherence to DMDs is a major challenge in the therapeutic management of MS. Nonadherence to DMDs among individuals with MS is associated with DMD related factors such as
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perceived/experienced lack of efficacy, injection site reactions, pain at injection sites, side
effects associated with DMDs, difficulty in self-injecting, and not being able to find someone to
give injection (Treadaway, 2009). According to a recent systematic review by Giovannoni
(2012), the average rate for stopping treatment with DMD among individuals with MS ranged
between 16% and 27%.
Satisfaction is the extent to which individual's experience match up to his or her
expectations (Pascoe, 1983). Satisfaction with medication is a significant predictor for
individuals to continue taking their medication, administering it in an appropriate manner, and
conforming to their treatment regimens (Anderson, 1999; Awad, 1999; Diamond, 1985; No
Author listed, 1998). Although studies have been done to assess satisfaction with specific
injection devices (Cramer, 2006), information on factors affecting treatment satisfaction in a
large sample of individuals with MS who are using different DMDs is still lacking. Clinical factors
such as disability, relapses, and symptoms associated with MS are known to affect health
related quality of life among individuals suffering from MS. Association of these factors with
satisfaction is also not known. Given the potential for DMDs to influence different aspects of
lives of individuals living with MS, it is essential to fill the current knowledge gaps with respect
to factors affecting their satisfaction with treatments and other important MS related factors.
Evaluating satisfaction levels among individuals with MS can help us understand whether
implicit expectations with respect to their treatments and other MS related factors are being
met are not.
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Methods
Participants
This was a cross sectional study among a group of individuals with a self-reported
clinician confirmed diagnosis of MS. Study participants were recruited using two separate
panels of individuals with MS in the US. Details of survey respondents are provided in Figure
4.1. The first panel comprised of individuals with MS who were subscribers of
www.MediGuard.org, which is a free medication monitoring service that provides individuals
with safety alerts, recalls, a check for drug interactions, and other drug related updates. The
second panel comprised of individuals with MS from Biogen Idec mailing list. Participants were
required to be 18 years of age or older, have a self-reported clinician confirmed diagnosis of
MS, and have a current residence in the US. A web based survey was developed using Qualtrics
survey builder and was administered from August 2011 through November 2011. All
respondents completing the survey received a $25 gift card as incentive for their participation.
This study was approved by the West Virginia University Institutional Review Board.
Study Variables
In this study, we collected information on the following categories of variables:
treatment satisfaction with medication, disability status, socio-demographic variables, MS
related, and DMD related Variables.
Treatment Satisfaction Questionnaire for Medication (TSQM) v.II
TSQM was used in this study to determine satisfaction with their MS medication (DMDs
if they were currently taking a DMD for treating their MS or non-DMD treatments in case
patients were not on any DMDs). TSQM v.II is an 11-item scale which is routinely used to assess
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patient satisfaction with medications. This questionnaire provides scores on four scales: Sideeffects (4 items), Effectiveness (2 items), Convenience (5 items), and Global satisfaction. The
psychometric properties of TSQM v.II scale are tested using a diverse patient population visiting
pharmacies to fill out a prescription for a new medication that they had never used previously
(Atkinson, 2005). The TSQM version 1.4 from which TSQM v.II is adapted has been validated in
a large population of individuals suffering from with eight different chronic conditions such as arthritis, asthma, major depression, type-I diabetes, high cholesterol, hypertension, migraine,
and psoriasis (Atkinson, 2004).
Patient Determined Disease Steps (PDDS)
In this study, the PDDS scale was used to describe current disability status in individuals
with MS. The advantage of using PDDS is that it is a self-administered scale which determines
functional disability in individuals with MS. The Kurtzke Expanded Disability Status Scale (EDSS),
a clinician based measure, is routinely used in clinical trials in MS as one of the clinical outcome
measures to evaluate disability progression over time using standard neurological examination
and to describe health states in MS. A strong correlation was observed between the EDSS and
PDDS score (Spearman rank correlation coefficient = 0.958) (Hohol, 1995). As PDDS scores
were reported to be comparable to the clinically utilized EDSS scale (Hohol, 1995), hence PDDS
was utilized as a surrogate measure for EDSS.
Socio-demographic Variables
The following patient demographic information was collected: age, gender, marital
status, race, education, income, employment, region, insurance status, panel
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(Mediguard/Biogen), total number of visits to primary care physician (PCP) in the past 12
months, and total number of visits to neurologists in the past 12 months.
MS and DMD related Variables
Information on the following MS related variables was collected: type of MS, duration of
MS, age at diagnosis, total number of MS related symptoms, total number of relapses
experienced in the last 12 month, and total number of comorbid conditions. In addition to the
disease related information, information on individuals’ current and past use of DMDs was also
obtained from self-report.
Statistical Analysis
Differences in socio-demographic, disease, and treatment related characteristics of the
respondents from the two panels were assessed using Pearson’s chi-square test for the
categorical variables, t-tests for normally distributed continuous variables, and Kruskal-Wallis
tests for continuous variables which did not have a normal distribution. Individuals’ sociodemographic, disease, and treatment related characteristics are reported as frequencies and
percentages for categorical variables, and continuous variables are presented with means and
standard deviations. Associations between individual’s characteristics and each of the 3
domains and the global satisfaction mean scores were analyzed using Mann-Whitney U test and
the Kruskal-Wallis one way ANOVA. Some of the variables were categorized in order to
meaningfully interpreting the results of bivariate analysis. PDDS score representing disability is
measured on an ordinal scale (Range 0-8). PDDS score was categorized into three categories,
mild, moderate, and severe, respectively (Marrie, 2006).
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Separate linear regression models were developed to identify disease and treatment
related factors that are significantly associated with 3 TSQM domain scores (Side effects,
Effectiveness, and Convenience) and Global satisfaction score with medication. Covariates
were entered into the model block-wise manner, first block included disease and treatment
related factors and in the second block socio-demographic variables were added.
Disease and treatment related factors assessed in the regression models included: type
of MS (RRMS as the reference category, SPMS, PPMS, PRMS), years since diagnosis of MS,
current age, number of MS symptoms experienced, number of relapses experienced in the past
12 months, number of comorbid conditions, PDDS score, number of DMDs taken in the past,
and type of current DMD used [Oral (Fingolimod) used as reference category, intramuscular
(IM) (Interferon b-1a), subcutaneous (SC) (Interferon b-1b), subcutaneous (SC) (Glatiramer
acetate), subcutaneous (SC) (Interferon b-1a), Infusion (Natalizumab), No DMD ]. Each
regression model was controlled for the following variables: age, gender [male as the reference
category, female], marital status [without a partner (single/living alone/divorced/widowed) as
the reference category, with a partner (married/living with partner)], race [White as the
reference category, Other], education [high school or less as the reference category, some
college, bachelors degree, postgraduate degree], income [≤$25,000 as the reference category,
$25,001 to $50,000, $50,001 to $75,000, $75,001 to $100,000, $100,001 or above],
employment [working full time as the reference category, working part time, not working (not
working/unable to work due to ms], region [northeast as the reference category, midwest,
south, west], prescription coverage [Not covered as the reference category, Covered, support
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program], panel [Biogen as the reference category, Mediguard], total PCP visits in the past 12
months, and total visits to neurologists in the past 12 months.
Individuals using mitoxantrone and those who were on the drugs from clinical trials
were excluded from the analysis. Multicollinearity check was performed before running the
regression models using the abovementioned independent variables.
The beta coefficients represent the degree to which treatment satisfaction scores with
medication would change with one unit change in the independent variable where the variable
is a continuous variable. Whereas if the independent variable is a categorical variable, the beta
coefficients represent the degree to which treatment satisfaction scores with medication would
change for a given category with respect to the reference category.
We had large enough sample size in comparison with the minimum sample size
estimated using accepted conventions for building power in multivariate regression
(Tabachnick, 1996; Pedhazur, 1997). All statistical analyses were conducted using IBM SPSS
20.0 (IBM Corp.).

Results
Survey Population Characteristics
Out of 3,743 individuals invited for participation from the two panels, 951 respondents
completed the survey questionnaire for this study (response rate of 25.4%). Breakdown of
respondents by different socio-demographic is provided in table 4.1, and MS and treatment
related characteristics are provided in table 4.2. A majority of the respondents were female
(84.6%), living with a partner (60.3%), white (86.9%), and with a mean age of 50.3 (SD ±9.9)
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years. Nearly one half of the respondents reported an annual household income of less than
$50,000. Very few (17.2%) respondents had less than or equal to a high school level education.
A majority of respondents (61.4%) were not employed at the time of their participation in this
survey. Respondents from all four geographical regions in the US participated in the survey.
Mean self-reported duration of multiple sclerosis was 11.4 years (SD ±8.2).
Approximately 80 percent of the survey respondents had relapsing-remitting form of MS.
The mean reported value for relapses experienced in the last 12 months was 1.4 (SD ±2.0), 8.2
(SD ±4.5) for experiencing MS related symptoms, 2.6 (SD ±2.2) for co-morbid conditions, and
1.1 (SD ±1.1) for the number of DMDs used in the past. A majority of the respondents reported
a current use of one of the approved DMDs to treat their MS. Mean score for self-reported
disability status was found to be 2.7 (±2.1) for the respondents. The average number of visits
to primary care physician in the past 12 months was 1.2 (±2.0) and the average number of visits
to the neurologist in the past 12 months was 2.4 (±1.9). A majority (73.1%) of the individuals
were taking a DMD at the time of the survey.
Comparison of respondent characteristics by panels (Biogen Vs Mediguard) is also
provided in tables 4.1 and 4.2, respectively. Respondents belonging to the Mediguard panel
were older [Mediguard 51.6 years (±9.4) Vs. Biogen 48.9 years (±10.2), p=<0.001], had been
living with MS for a longer duration [Mediguard 13.8 years (±8.4) Vs. Biogen 8.9 years (±7.1),
p=<0.001], and had experienced more number of relapses [Mediguard 1.8 (±2.3) Vs. Biogen 1.0
(±1.6), p=<0.001] in the past 12 months. Whereas respondents belonging to Biogen panel had
relatively fewer MS related symptoms [Biogen 7.2 (±4.4)Vs. Mediguard 9.1 (±4.3), p=<0.001],
fewer co-morbid conditions [Biogen 2.0 (±1.9) Vs. Mediguard 3.2 (±2.4), p=<0.001], lower levels
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of disability [Biogen 2.1 (±1.9) Vs. Mediguard 3.2 (±2.1), p=<0.001], and fewer primary care
physician visits in the past 12 months [Biogen 0.8 (±1.5) Vs. Mediguard 1.5 (±2.2), p=<0.001].
Average number of visits to neurologists in the past 12 months was higher for respondents in
the Biogen panel [Biogen 2.5 (±2.0) Vs. Mediguard 2.2 (±1.8), p=<0.05]. There were no
significant difference in the respondents of the two panels with respect to marital status,
region, and prescription coverage.
Univariate Analysis
Treatment satisfaction scores for Convenience, Side-effects, and Effectiveness domains
along with the Global satisfaction scores by individual characteristics are reported in the table
4.3. The results suggest there is a statistically significant difference in the distribution of mean
TSQM scale scores and Global satisfaction scores between individuals based on the type of
current DMD used. [For example, the mean TSQM-global satisfaction scores based on the type
of current DMD used: IM (Interferon b-1a) -78.5 (±18.4) Vs SC (Interferon b-1b) - 68.5 (±13.5) Vs
SC (Glatiramer acetate) - 72.9 (±20.8) Vs Oral (Fingolimod)] - 85.6 (±19.2) Vs SC (Interferon b-1a)
- 75.2 (±16.2) Vs Infusion (Natalizumab) - 83.5 (±17.2) Vs No DMD - 50.1 (±27.7), p= <0.001]
Linear Regression analyses
Linear regression models were adjusted for the following covariates: gender, marital
status, race, education, income, employment status, region, panel, prescription coverage,
primary care physician visits in the past 12 months, and visits to neurologists in the past 12
months (Table 4.4). Type of current DMD used was significantly associated with Convenience,
Effectiveness, and Global satisfaction scores. Respondents taking IM-interferon b-1a (β=-25.58,
p < 0.001), SC-interferon b-1b (β=-30.05, p < 0.001), SC-glatiramer acetate (β=-27.19, p < 0.001),
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SC-interferon b-1a (β=-25.99, p < 0.001), Infusion-natalizumab (β=-15.49, p < 0.001) (any of the
available parenteral DMDs), and those who were not on any DMD (β=-35.07, p < 0.001) had
lower Convenience scores as compared to those who were using oral (fingolimod) DMD. Those
who were currently taking infusion-natalizumab (β= 7.95, p < 0.05) had higher Effectiveness
scores as compared to those who were using oral-fingolimod. Respondents currently not
taking any DMD (β= -23.06, p < 0.001) had significantly lower Effectiveness domain scores as
compared to those who were using oral-fingolimod. Respondents taking IM-interferon b-1a
(β=-15.76, p < 0.001), SC-interferon b-1b (-21.13, p < 0.001), SC-glatiramer acetate (β=-16.66, p
< 0.001), SC-interferon b-1a (β=-14.81, p < 0.001), or no DMD (β=-36.59, p < 0.001) had
significantly lower Global satisfaction scores as compared to those who were using oralfingolimod. The Global scores for those who were taking natalizumab-infusion did not differ
from those who were using oral-fingolimod. Side-effect scores did not significantly differ
between those who were taking oral-fingolimod and those who were users of other type of
DMDs or the non users.
Increasing MS related symptoms experienced by an individual was negatively associated
with the satisfaction scores in all the models (Convenience β=-0.64, p < 0.01; Effectiveness β=0.94, p<0.05; Side-effects β =-1.26, p<0.001; Global β = -0.82, p<0.001). Number of relapses
experienced in the past 12 months was negatively associated with satisfaction scores
(Convenience β=-0.93, p < 0.05; Effectiveness β=-1.89, p<0.05; Side-effects β =-1.06, p<0.05;
Global β = -1.31, p<0.001). Presence of comorbid conditions had a negative association with
Side-effects domain scores (Side-effects β =-0.90, p<0.05). Increase in the PDDS score
(indicating increasing level of disability) was associated with lower Effectiveness and Global
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satisfaction scores (Effectiveness β=-1.78, p<0.05; Side-effects β =-1.44, p<0.01). Experience of
using DMDs in the past was negatively associated with Effectiveness, Side-effects, and Global
satisfaction scores (Effectiveness β=-1.97, p<0.05; Side-effects β =-2.30, p<0.01; Global β = 2.16, p<0.01). The proportion of variance explained in the satisfaction scores did not change
after the inclusion of socio-demographic factors in the models (Table 4.5).

Discussion
In this cross-sectional study of a national sample, we evaluated factors that are
associated with treatment satisfaction among individuals living with MS. Of all the factors that
were evaluated, number of MS related symptoms and number of relapses experienced in the
past 12 months were found to be consistently and significantly associated with lower overall
and domain specific satisfaction scores on TSQM. Disability status, number of DMDs taken in
the past, and type of DMD that is used currently by the respondents were significantly
associated with the overall treatment satisfaction.
Unpredictable relapses are characteristic of MS. Disability related to MS is the result of
partial recovery following a relapse or worsening that is independent of relapse in case of
progressive forms of MS (Tremlett, 2009). Lesions that are formed in the brain and the
neuronal damage taking place in different parts of the central nervous system (CNS) in course
of MS manifest into different types of physical and cognitive symptoms that eventually progress
to some form of disability (Compston, 2002). Symptoms experienced in MS differ depending on
the magnitude and the part of the CNS that is affected. Irrespective of the type of MS, patients
often experience different types of symptoms which affect their quality of life (Rudick, 2008).
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Disease modifying drugs used in MS treatment are used to reduce relapse rates thereby
delaying the accumulation of disability and the resultant progression of MS (Thompson, 2001).
Thus, DMDs may also reduce the symptoms experienced by the individuals with MS (Zwibel,
2011).
In this study, disability status was evaluated using a self-reported measure (PDDS) for
individuals with MS. Higher score on PDDS indicated higher levels of disability. Higher PDDS
scores were found to be negatively associated with Effectiveness and Global satisfaction scores.
This finding suggests that perceived or actual disability of individuals with MS is an important
determinant for perceived effectiveness and overall satisfaction with their treatments. The
number of relapses in the past 12 months and total number of MS symptoms experienced by
the individuals also had a negative association with all the TSQM domain scores along with the
global satisfaction score.
In this study, the number of comorbid conditions was negatively associated with the
Side-effects score. Studies have shown that individuals with MS with other comorbid
conditions experience a lower HRQoL (Marrie, 2011). Side effects, such as injection site
reactions, flu-like symptoms, chill, fever, and nausea (Coles, 2009; Treadaway, 2009) are
common to DMDs used in MS. Such side effects may possibly add to the overall HRQoL, clinical,
economic burden on individuals if they are also suffering from other comorbid conditions. Total
number of primary care physician visits in the past 12 months was negatively associated with
Side-effects score. An explanation to this association could be that the individuals with MS
experiencing side effects due to their treatments had to visit their primary care physicians more
often than others to take care of the side effects related issues.
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Another factor that was found to be associated with lower Effectiveness, Side-effects,
and Global scores was the number of DMDs taken in the past. Past use of multiple DMDs may
imply switching/stopping behavior on part of individuals due to several reasons including, but
not limited to, inefficacy of the DMD, side effects, and costs. Although evaluation of
individual’s treatment satisfaction with medication is targeted towards assessing experiences
with current medication; individual’s assessment of current medication could be influenced by
their past medication experiences. Past medication experiences could play a role in setting
expectations prior to initiating new medication (Atkinson, 2005).
Medications with oral route of administration are reported to have better mean
satisfaction scores for convenience in chronic conditions (Atkinson, 2004). With almost all
DMDs being parenteral, except fingolimod, inconvenience of administration is a major factor
affecting adherence with at least the first line DMDs. In this study, individuals who were
parenteral DMD users and DMD non-users had significantly lower mean scores for satisfaction
with Convenience as compared to mean scores for those who were taking oral-fingolimod.
Individuals with MS on once a month infusion-natalizumab indicated significantly higher
satisfaction scores for effectiveness as compared to those who were on once a day oralfingolimod. Although there are no head-to-head comparisons for these two DMDs used in MS,
a recent cost-effectiveness study comparing these two DMDs found that natalizumab is
cheaper and more effective (O'Day, 2011). Global satisfaction scores were not significantly
different for individuals who were on once a month infusion-natalizumab as compared to those
who were on oral-fingolimod DMD.
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MS is a lifelong disease without a cure; hence, long-term treatment with DMDs is
imperative. In addition, MS affects young adults hence they are expected to be on DMD early
on and would be required to take these DMDs for longer durations. It is suggested that DMD
initiation be done early in the course of MS in order to delay the progression. However
problems associated with currently available DMDs such as, parenteral routes of
administration, safety and tolerability issues, long duration of treatments, perceived lack of
efficacy, and side effects associated with the DMDs have contributed considerably towards low
treatment satisfaction possibly reducing adherence and persistence with DMD treatment.
When individuals discontinue following their prescribed medication regimen, individuals fail to
get optimum treatment benefits. Adherence with treatments has shown to improve clinical,
quality of life, and economic outcomes for individuals with MS over a period of time. Hence,
periodic evaluation of treatment satisfaction in individuals with MS with respect to DMDs will
help providers better understand factors affecting adherence issues with treatment.
Following limitations of this study should be noted. As this study collected self-reported
data from individuals with MS, there is a potential for social desirability or reporting bias. Data
collection was carried out using two panels and the sample differences might introduce
selection bias and can limit the generalizability of the results. However, the multivariate
models were controlled for panel affiliation. This was a cross-sectional study hence causation
cannot be established. Current adherence levels, perception of risks, and individual’s
experiences with past MS medications may affect expectations from current DMDs and in turn
may affect satisfaction scores. Such information was not collected. Information related to
respondents’ expectations from their current treatment, reasons for stopping/switching
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previous treatments, and treatment related side effects experienced by them were not
collected.
Conclusion
This cross-sectional survey suggests that treatment satisfaction among individuals with
MS is related to factors such as relapse, disability status, MS symptoms, past experiences with
DMDs, and primarily the type of current DMD. With the likely increase in DMD options and
uncertainty with respect to the safety-efficacy profile of future DMDs, engagement of
individuals with MS in treatment related decisions has become imperative. Assessing
treatment satisfaction routinely can help clinicians and other care providers better understand
value judgment of individuals with MS with respect to their DMDs.
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Table 4.1: Summary of participants’ sociodemographic characteristics

Characteristic
Age
Gender
Marital Status
Race

Education

Income

Employment

Region

Prescription
Coverage

Categories

Total
%/SD

Biogen

Mean (SD)
Female
Male
Without partner
With partner
White
Other
High school or Less
Some college
Bachelors Degree

50.3 (9.9)
798 (84.6)
145 (15.4)
375 (39.7)
570 (60.3)
822 (86.9)
124 (13.1)
163 (17.2)
392 (41.4)
276 (29.2)

Postgraduate Degree

Mediguard

Sig.

48.9 (10.2)
371 (82.1)
81 (17.9)
170 (37.4)
285 (62.6)
375 (82.4)
80 (17.6)
61 (13.4)
178 (39.1)
146 (32.1)

51.6 (9.4)
427 (82.1)
64 (13.0)
205(41.8)
285 (58.2)
447 (91.0)
44 (9.0)
102 (20.8)
214 (43.6)
130 (26.5)

***
*

115 (12.2)

70 (15.4)

45 (9.2)

<$25,000
$25,001-$50,000
$50,001-$75,000
$75,001-$100,000
>$100,000
Full time
Part time

244 (25.8)
273 (28.9)
215 (22.8)
118 (12.5)
95 (10.1)
255 (27.0)
110 (11.6)

82 (18.0)
137 (30.1)
109 (24.0)
71 (15.6)
56 (12.3)
169 (37.1)
55 (12.1)

162 (33.1)
136 (27.8)
106 (21.6)
47 (9.6)
39 (8.0)
86 (17.5)
55 (11.2)

Not Working

581 (61.4)

231 (50.8)

350 (71.2)

Northeast
Midwest
South
West
Covered
Support Program
Not Covered

204 (21.6)
249 (26.3)
307 (32.5)
186 (19.7)
832 (87.8)
43 (4.5)
73 (7.7)

92 (20.2)
110 (24.2)
159 (34.9)
94 (20.7)
404 (88.0)
22 (4.8)
33 (7.2)

112 (22.8)
139 (28.3)
148 (30.1)
92 (18.7)
428 (87.5)
21 (4.3)
40 (8.2)

*0.01≤p<0.05, **0.001≤p<0.01, ***p<0.001
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0.160
***
***

***

***

0.222

0.803

Table 4.2: Summary of participants’ multiple sclerosis and treatment related characteristics
Characteristic

Type of MS

Total
%/SD

Categories
RRMS
SPMS
PPMS
PRMS

Biogen

Mediguard

Sig.

769 (80.9) 415 (90.4)
96 (10.1)
24 (5.2)
49 (5.2)
10 (2.2)
37 (3.9)
10 (2.2)

354 (72.0)
72 (14.6)
39 (7.9)
27 (5.5)

***

***

Duration of MS

Mean (SD)

11.4 (8.2)

8.9 (7.1)

13.8 (8.4)

Number of MS
symptoms

Mean (SD)

8.2 (4.5)

7.2 (4.4)

9.1 (4.3)

Mean (SD)

1.4 (2.0)

1.0 (1.6)

1.8 (2.3)

Mean (SD)

2.6 (2.2)

2.0 (1.9)

3.2 (2.4)

Mean (SD)

1.1 (1.1)

1.0 (1.1)

1.1 (1.2)

258 (27.1) 201 (43.8)
40 (4.2)
12 (2.6)
129 (13.6)
42 (9.2)
44 (4.6)
21 (4.6)
79 (8.3)
23 (11.4)
145 (15.2) 126 (27.5)
256 (26.9)
34 (7.4)
2.7 (2.1)
2.1 (1.9)

57 (11.6)
28 (5.7)
87 (17.7)
23 (4.7)
56 (5.0)
19 (3.9)
222 (45.1)
3.2 (2.1)

Relapses in past
12 months
Number of comorbidities
Number of past
DMDs

Type of current
DMD used

PDDS

IM (Interferon b-1a)
SC (Interferon b-1b)
SC (Glatiramer acetate)
Oral (Fingolimod)
SC (Interferon b-1a)
Infusion (Natalizumab)
No DMD
Mean (SD)

Primary care
physician visits
in past 12
months

Mean (SD)

1.2 (2.0)

0.8 (1.5)

1.5 (2.2)

Neurologist
visits in past 12
months

Mean (SD)

2.4 (1.9)

2.5 (2.0)

2.2 (1.8)

*0.01≤p<0.05, **0.001≤p<0.01, ***p<0.001
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***
***
***
***
***

***
***

*

<40yrs
40-<50yrs
50-<60yrs
>60yrs

Full time
Part time
Not Working

<$25,000
$25,001-$50,000
$50,001-$75,000
$75,001-$100,000
>$100,000
Employment

Income

High school or Less
Some college
Bachelors Degree
Postgraduate Degree

Female
Male
Marital Status
With partner
Without partner
Race
White
Other
Education

Gender

Age

Characteristic

***
71.8 (21.2)
74.3 (19.1)
70.1 (23.2)

70.4 (23.7)
72.2 (21.8)
69.5 (21.3)
72.4 (20.0)
71.5 (24.7)
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*

0.280

0.590

0.862

0.525

0.912

*0.01≤p<0.05, **0.001≤p<0.01, ***p<0.001

75.5 (23.0)
76.8 (18.1)
67.0 (26.0)

65.6 (26.2)
72.0 (24.0)
72.1 (23.6)
74.0 (21.8)
70.5 (28.1)

*

72.0 (21.9)
70.4 (21.7)

72.7 (23.3)
70.1 (25.8)

70.8 (22.4)
72.8 (21.3)

70.8 (22.3)
71.3 (22.2)

74.2 (22.0)
70.4 (22.3)

73.9 (20.5)
70.5 (21.6)
70.9 (22.6)
69.0 (24.3)

0.433

TSQM Convenience
Mean ±SD
Sig.

70.4 (22.6)
70.8 (22.6)

0.461

*

0.329

0.194

**

Sig.

69.7 (24.5)
69.3 (25.7)

69.7 (25.3)
75.6 (20.3)

71.2 (24.2)
69.3 (25.6)

70.1 (24.7)
72.3 (25.6)

75.8 (23.3)
70.0 (23.2)
69.5 (25.4)
67.0 (27.0)

TSQM Global
Mean ±SD

77.0 (23.7)
74.2 (23.3)
66.2 (29.2)

63.8 (31.0)
69.3 (26.5)
72.2 (25.7)
77.1 (24.7)
74.4 (26.2)

73.3 (25.6)
74.8 (24.8)

66.6 (28.3)
67.7 (29.2)

70.2 (27.8)
69.2 (26.1)

70.8 (27.3)
68.8 (28.1)

73.0 (26.9)
69.4 (27.8)

70.6 (27.0)
68.4 (27.6)
71.0 (27.9)
69.3 (28.0)

***

***

*

0.490

0.304

0.151

0.603

TSQM Side-effects
Mean ±SD
Sig.

70.3 (24.0)
70.2 (21.8)
57.4 (25.7)

56.0 (27.3)
62.0 (25.0)
66.9 (23.8)
66.8 (23.2)
63.6 (26.2)

64.7 (25.0)
63.1 (27.1)

59.4 (24.7)
61.7 (25.7)

61.4 (26.0)
68.7 (21.6)

63.7 (24.7)
60.3 (26.7)

64.3(26.0)
62.1 (25.5)

69.9 (23.2)
62.0 (24.3)
60.7 (25.8)
57.8 (27.5)

***

***

0.152

**

0.084

0.306

***

TSQM Effectiveness
Mean ±SD
Sig.

Table 4.3: TSQM scores by participants’ sociodemographic, disease, and treatment related characteristics

Biogen
Mediguard

6-10 symptoms
11-15 symptoms
≥16 symptoms

<5yrs
5-<10yrs
10-<20yrs
>20yrs
MS related symptoms
0 symptom
1-5 symptoms

Type of MS
RRMS
SPMS
PPMS
PRMS
Duration of MS

Panel

***

***

***

***

75.6 (16.8)
74.9 (19.4)
70.8 (21.9)
68.7 (24.1)
63.3 (26.9)

71.7 (20.30
73.3 (21.8)
69.0 (24.0)
69.3 (22.3)

72.0 (21.4)
68.9 (23.6)
65.0 (27.8)
65.3 (26.0)

75.4 (19.8)
67.1 (23.6)

71.3 (22.4)
71.9 (18.5)
67.9 (22.3)

71.3 (22.4)
67.8 (23.9)
73.7 (20.8)
70.9 (21.7)
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**

0.107

0.129

***

0.331

0.060

TSQM Convenience
Mean ±SD
Sig.

*0.01≤p<0.05, **0.001≤p<0.01, ***p<0.001

91.6 (10.5)
78.5 (20.0)
69.7 (24.0)
63.7 (26.8)
59.2 (29.5)

72.8 (22.6)
74.2 (23.8)
68.7 (25.7)
62.7 (26.0)

73.3 (22.8)
59.2 (29.9)
54.4 (29.1)
63.9 (27.7)

78.1 (20.7)
63.5 (26.2)

70.6 (25.0)
74.8 (21.4)
67.2 (24.5)

0.262

Covered
Support Program
Not Covered

70.3 (25.1)
69.3 (25.5)
71.9 (24.3)
69.8 (24.5)

Northeast
South
West
Midwest
Prescription Coverage

Sig.
0.584

TSQM Global
Mean ±SD

Region

Characteristics

91.1 (15.9)
80.0 (22.3)
70.3 (26.5)
59.7 (28.5)
56.1 (32.9)

72.2 (25.5)
70.9 (27.3)
68.8 (29.0)
67.2 (28.2)

71.6 (26.8)
68.5 (29.3)
57.4 (31.5)
57.6 (26.0)

75.2 (24.8)
65.2 (29.1)

70.6 (27.4)
66.2 (25.0)
65.2 (30.3)

70.2 (27.8)
69.6 (28.8)
70.4 (27.4)
69.8 (26.4)

***

0.419

***

***

0.181

0.969

TSQM Side-effects
Mean ±SD
Sig.

91.1 (8.3)
72.7 (23.1)
60.9 (24.1)
54.7 (25.0)
46.7 (26.3)

66.6 (23.4)
67.1 (24.3)
59.4 (26.7)
52.5 (25.4)

65.8 (23.9)
48.1 (29.3)
44.2 (25.7)
54.7 (24.4)

70.7 (23.1)
54.8 (25.3)

62.6 (25.6)
65.5 (22.4)
59.1 (26.6)

62.2 (25.7)
60.5 (25.4)
63.9 (25.5)
62.4 (25.7)

***

***

***

***

0.432

0.418

TSQM Effectiveness
Mean ±SD
Sig.

Continued - Table 4.3: TSQM scores by participants’ sociodemographic, disease, and treatment related characteristics

59.0 (26.9)
71.5 (24.4)

Neurologists in past 12 months
No neurologists visit
At least one neurologists visit

***

***

***

***

***

***

Sig.
*

TSQM Convenience
Mean ±SD
Sig.
0.792
72.3 (20.6)
71.2 (21.4)
70.3 (24.5)
0.129
72.9 (20.0)
70.6 (24.0)
68.8 (24.1)
**
73.5 (21.0)
70.6 (21.5)
68.4 (23.5)
***
73.0 (19.3)
66.9 (15.3)
69.6 (20.6)
95.3 (8.3)
70.5 (17.4)
82.0 (17.2)
60.4 (25.6)
0.910
71.4 (19.8)
70.9 (22.3)
70.9 (25.0)
0.408
72.2 (20.0)
69.6 (24.7)
**
62.0 (25.7)
71.8 (21.8)
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*0.01≤p<0.05, **0.001≤p<0.01, ***p<0.001

73.2 (22.8)
67.1 (26.7)

75.0 (20.7)
69.8 (25.0)
65.5 (28.1)

78.5 (18.4)
68.5 (13.5)
72.9 (20.8)
85.6 (19.2)
75.2 (16.2)
83.5 (17.2)
50.1 (27.7)

76.6 (23.1)
68.7 (23.6)
64.3 (25.7)

76.2 (21.1)
70.6 (25.4)
62.8 (27.0)

77.0 (21.3)
71.0 (23.7)
66.6 (27.6)

TSQM Global
Mean ±SD

Total number of past DMDs
0PastDMD
1 Past DMD
≥2 Past DMDs
Primary care physician visits in past 12 months
No primary care physician visit
At least one primary care physician visit

Oral (Fingolimod)]
SC (Interferon b-1a)
Infusion (Natalizumab)
No DMD

1 Relapse
≥2 Relapses
Type of current DMD used
IM (Interferon b-1a)
SC (Interferon b-1b)
SC (Glatiramer acetate)

Moderate disability
Severe disability
Relapses in the last 12 month
No relapse

Comorbid conditions
No co-morbid condition
1-3 comorbid conditions
≥4 comorbid conditions
Disability (PDDS)
Mild disability

Characteristics

TSQM Side-effects
Mean ±SD
Sig.
***
81.4 (20.5)
71.3 (26.6)
62.2 (30.2)
***
74.0 (25.4)
68.7 (27.4)
65.3 (29.7)
***
77.0 (25.2)
69.0 (27.7)
62.1 (28.0)
***
73.3 (22.9)
67.5 (23.7)
77.5 (26.5)
65.9 (32.8)
70.7 (22.2)
76.8 (25.8)
60.0 (31.4)
**
74.5 (23.7)
69.0 (28.9)
65.3 (30.0)
***
75.1 (25.0)
63.6 (29.4)
***
61.1 (30.8)
70.8 (27.2)

TSQM Effectiveness
Mean ±SD
Sig.
*
69.1 (23.9)
63.6 (25.0)
57.0 (26.5)
***
70.4 (23.0)
60.1 (25.4)
52.6 (25.4)
***
70.6 (24.5)
59.8 (23.5)
54.2 (24.8)
***
73.3 (20.9)
65.4 (17.6)
65.3 (21.5)
64.3 (21.7)
64.3 (17.0)
75.6 (18.9)
41.3 (25.8)
***
69.1 (23.8)
61.0 (24.9)
55.3 (26.2)
**
64.9 (23.9)
59.4 (27.1)
***
51.3 (28.8)
63.4 (25.0)
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Table 4.4: Results of linear regression analysis
Independent Variables

TSQM Convenience
Model 1
Model 2

Type of MS (Ref. RRMS)
SPMS
2.13
2.06
PPMS
2.52
2.11
PRMS
-0.73
-1.17
Duration of MS
0.17
0.19
Age in years
0.01
-0.01
No. of MS symptoms
-0.58**
-0.64**
No. of Relapses in last 12
-0.68
-0.93*
months
No. of comorbid condition
0.54
0.49
PDDS
-0.17
-0.47
No. of DMDs taken in the
-1.02
-1.29
past
Type of current DMD used [Ref. Oral (Fingolimod)]
IM (Interferon b-1a)
-26.19*** -25.58***
SC (Interferon b-1b)
-31.13*** -30.05***
SC (Glatiramer acetate)
-28.08*** -27.19***
SC (Interferon b-1a)
-27.33*** -25.99***
Infusion (Natalizumab)
-14.34*** -15.49***
No DMD
-36.75*** -35.07***
Gender (Ref. Males)
-2.19
Marital (Ref. without
-0.65
partner)
Race (Ref. White)
-0.99
Education (Ref. ≤High school)
Some college
-0.29
Bachelors Degree
-0.09
Postgraduate Degree
-0.73
Income (Ref. <$25,000)
$25,001-$50,000
-1.16
$50,001-$75,000
-3.91
$75,001-$100,000
-3.50
>$100,000
-3.14
Employment (Ref. Full time)
Part time
2.05
Not Working
2.58
Region (Ref. Northeast)
Midwest
-2.26
South
2.04
West
-0.95
Panel (Ref. Biogen)
-1.91
Prescription Coverage (Ref. Not covered)
Covered
1.06
Support Program
-0.12
No. of visits to PCP in past
0.08
12 months
No. of visits to Neurologists
0.72
in past 12 months

TSQM Effectiveness
Model 1
Model 2

TSQM Side-effects
Model 1
Model 2

TSQM Global
Model 1
Model 2

-2.64
-1.62
3.11
0.01
0.01
-0.88***
-1.74***

-2.45
-1.36
2.92
0.02
0.02
-0.94*
-1.89*

3.57
-3.01
-5.49
0.05
0.19
-1.39***
-1.39**

2.58
-2.94
-4.19
0.09
0.14
-1.26***
-1.06*

-2.33
-0.79
2.28
0.16
0.05
-0.76***
-1.14**

-1.74
-0.68
2.72
0.17
0.07
-0.82***
-1.31***

0.49
-1.78***
-1.96**

0.48
-1.78*
-1.97*

-1.10**
-0.13
-2.33**

-0.90*
0.31
-2.30**

0.43
-1.25**
-1.98**

0.43
-1.44**
-2.16**

-0.22
-2.00
-2.75
-4.03
8.66*
-22.82***

-0.86
-2.31
-3.05
-4.31
7.95*
-23.06***
- 0.72
0.68

-3.58
-4.09
5.99
-1.79
5.89
-8.10

-3.82
-3.82
7.04
-0.25
5.62
-7.02
-0.63
-1.57

-15.05***
-21.00***
-16.71***
-14.75***
-4.22
-36.90***

-15.76***
-21.13***
-16.66***
-14.81***
-5.32
-36.59***
-0.68
-0.10

1.47

-3.42

1.14

0.43
0.49
-1.93

0.82
3.50
1.65

-1.88
-0.63
-3.22

-0.69
0.99
-2.37
-3.23

2.35
2.64
5.10
4.07

0.62
-1.22
-2.31
-3.41

1.24
-0.74

-2.67
-2.04

1.59
1.22

-0.82
0.22
-1.27
-0.75

1.34
0.33
-0.55
-2.58

-0.33
-0.33
-2.33
-1.72

-2.42
-2.11
0.72

0.22
-2.51
-0.95*

-1.69
-0.94
0.17

-0.02

-0.35

0.28

*0.01≤p<0.05, **0.001≤p<0.01, ***p<0.001
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Table 4.5: Summary of the block-wise entry of covariates in the linear regression models
Model

R2

Adj. R2

R2 Change

F change

Dependent variable: TSQM- Convenience domain score
1
0.186
0.171
0.186
13.034
2
0.204
0.172
0.019
1.051
Dependent variable: TSQM- Effectiveness domain score
1
0.390
0.379
0.390
36.574
2
0.398
0.374
0.008
0.598
Dependent variable: TSQM- Side-effects domain score
1
0.178
0.164
0.178
12.379
2
0.195
0.163
0.017
0.970
Dependent variable: TSQM- Global score
1
0.345
0.333
0.345
30.064
2
0.353
0.327
0.009
0.607

F change
Sig.

Model F
statistic

Sig. F
Change

***
.398

13.034
6.383

***
***

***
.916

36.574
16.444

***
***

***
.497

12.379
6.037

***
***

***
.910

30.064
13.584

***
***

*0.01≤p<0.05, **0.001≤p<0.01, ***p<0.001
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Figure 4.1: Survey population
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CHAPTER 5

SUMMARY AND CONCLUSION

Rational and Objective
Although incurable in nature, multiple sclerosis (MS) can be effectively managed with
strategies that primarily include use of treatments intended for modifying the course of the
disease, reducing frequency of relapses, and managing symptoms effectively. Disease modifying
drugs (DMDs) used in MS are clinically proven to decrease the occurrence of relapses and delaying
worsening of condition which eventually help keeping physical and cognitive disabilities at bay.
Improvements in the magnetic resonance imaging techniques and the changes in the criteria used
for diagnosis allow early diagnosis of MS in individuals (Cohen, 2006) thereby increasing the
possibility of treating individuals with MS early with DMDs. Early initiation of DMDs in the clinical
course of the disease is expected to prevent irreversible damage (Alkhawajah, 2011). Currently
available first line injectable DMDs (interferon beta 1a/1b and glatiramer acetate) are relatively less
effective than the second line DMDs (natalizumab and mitoxantrone) but are relatively safer than
the second line DMDs. Fingolimod, the first ever oral DMD for MS, was approved by the United
States Food and Drug Administration (USFDA) in 2010 as a first line therapy whereas it was
approved as a second line therapy by the European Medicines Agency (EMA). However, it came
under tough scrutiny of regulators in the US and Europe after receiving reports of deaths among
individuals with MS who were on it. It is likely that the regulators may provide fingolimod under
restricted access programs and will increase monitoring for individuals who will use it.
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Adhering and continuing to take prescribed DMD as suggested by the clinician is one of the
best possible approach individuals with MS can adopt in successfully managing their MS. As
therapeutic management of MS requires patients to take their DMDs for an extended period time,
adherence with DMDs may become challenging. Adherence to the DMDs is affected due to the
side-effects associated with them. Patients have often reported factors associated DMDs such as
needle phobia, difficulty in self injecting, injection site reactions, discomfort in self injecting,
perceived/experienced lack of efficacy, injection site reactions, pain at injection sites, side effects
associated with DMDs (flu-like symptoms, headaches, and nausea), not being able find someone to
give injection, and perceived risk of adverse events associated DMDs (Panitch, 2002; Cox, 2006; Rio,
2005; Samuel, 2006; Cramer, 2006; Treadaway, 2009). Non-adherence to DMDs may have clinical,
economics, physical, psychological, and social consequences.
Selection of DMDs is an important step in forming an effective treatment strategy in MS.
Due to the a) increasing choices for DMDs, b) concerns around uncertainty of the safety-efficacy
profiles, and c) the unavailability of the long term data on the newer DMDs; participation of
individuals with MS in the process of treatment selection have become ever more important.
Involvement of patients in making decisions related to DMD is necessary in order to provide patient
centered care (Edwards, 1999). Rigorous assessment of individual’s experiences with current/past
DMDs, expectations from future DMDs, understanding of risks and benefits, preferences for
benefits and risks, and different factors associated with treatment satisfaction are required.
This dissertation project utilizes qualitative and quantitative research methods to study
important aspects associated with DMDs. The objective of the first study of this project was to do a
qualitative assessment of experiences, perceptions, and expectations of individuals with MS with
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DMDs. The second study focused on quantifying preference weights and relative importance of
attributes related to DMDs used in the treatment of MS using conjoint analysis. Lastly, the purpose
of the third study was to determine disease and treatment related factors associated with
treatment satisfaction in individuals with multiple sclerosis. Qualitative data collection for the first
study involved focus group discussions with MS patients in an academic hospital setting and the
remaining two studies included web based self-report surveys of individuals with MS living in the
US. The research design employed in this project was cross sectional.

Summary of Findings
A total of 18 individuals with confirmed diagnosis of MS participated in the qualitative
study. Content analysis of the focus group transcripts revealed five major themes: a) positive
experiences of DMDs, b). negative experiences of DMDs, c) DMD adherence, d) perceived/actual
value of DMDs, e) expectations from future DMDs. All participants of the focus group had a good
understanding of the role of DMDs in the overall MS treatment. A majority of participants believed
that the DMDs they were taking were effective in preventing their relapses and progression of the
disease. Participants believed that reduction in frequency of relapses was the most significant
benefit that they had experienced, followed by improvements in quality of life, physical health,
cognitive health, and energy levels. Perceived or experienced lack of efficacy, injection site
reactions, and side effects of DMDs that affected individuals’ day to day lives were the negative
experiences that participants believed are associated with DMDs.
Although none of the participants in our study had previously experienced any adverse
events from DMDs, they expressed a general concerns about the risks associated with DMDs.
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Adherence with DMDs among participants was affected due to perceived/actual efficacy,
convenience of administration, dosage frequency, administration flexibility, perceived quality of
life, ability to self-inject, finding help to give injections, forgetting to take it, insurance coverage,
and not having enough medicine. Majority of the participants reported having some form of
health insurance and prescription coverage. Hence cost of DMD was not an issue them. They
hoped that their coverage and co-pays do not increase in the future and remain the same.
Participants’ perceived non-monetary valuation of DMDs was related to perceived clinical benefit,
quality of life, and severe adverse events, perceived cost of missed opportunity to initiate
treatment with DMD after initial diagnosis, and perceived diminishing benefit from DMDs.
Participants expected to see newer DMDs that would repair damaged myelin, more oral
treatments, improve quality of life, and treatments serve as a cure for MS. Although, a majority of
the participants indicated that they would prefer oral DMDs over injectable DMDs, interestingly,
they expressed their hesitation and concerns over the strength of safety-efficacy data associated
with the newer DMDs.
The second study utilized a choice based, stated preference method to estimate preference
weights and relative importance of attributes for DMDs used in the treatment of MS. DMDs were
defined using seven characteristics unique to DMDs indicating mode of administration, evidence on
treatment outcomes in years, number of relapses expected within 5 years, delay in disability
progression by ‘n’ years, chances of severe disability or death from PML in within 5 years, chances
of severe liver dysfunction within 5 years, and chances of flu-like symptoms following DMD
administration. Each DMD had three levels. Estimated preference weight indicated a natural order
of preference suggesting that respondents understood the differences in the three attribute levels
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in the choice tasks. Respondents placed a higher utility for lower levels associated with risk related
attributes (PML, liver dysfunction, and flu-like symptoms). Higher utility was indicated for benefits
providing larger gains in terms of no relapse within next 5 years and delaying progression of MS by
15 years. Respondents also indicated higher preferences for DMD with oral route of administration
over parenteral DMDs. The need for DMDs with better safety-efficacy is data is reflected in
patients’ choice of DMDs with 15 years of research over relatively less studied DMDs. Attributes
indicating risk related DMDs; such as liver dysfunction and PML were relatively the most important
to the respondents. Remaining attributes were ranked in the following order- flu-like symptoms,
delaying progression of MS, relapses within 5 years, treatment administration, and evidence on
outcomes.
The objective of the third study was to assess disease and treatment related factors
associated satisfaction of treatment in individuals with MS. Respondents currently not taking any
DMD had consistently lowest mean treatment satisfaction scores for all the three domains and the
global satisfaction scores as compared those who were on DMDs. After controlling for various
socio-demographic factors, type of current DMD used, total number of DMDs taken in the past,
number of relapses MS symptoms experienced, number of relapses experienced in the past 12
months, and the disability status score were found to have significant negative association with the
treatment satisfaction scores. Satisfaction score for convenience of administration were
significantly better for those who were on once a day oral (fingolimod) formulation than for those
respondents who were on injectable DMDs or on no DMD. This confirms that for MS patients, oral
treatments are associated with higher levels satisfaction with convenience of administration.
Respondents who were on once a month infusion (natalizumab) had significantly better
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effectiveness scores as compared to the latest oral (fingolimod) DMD. None of the treatments
(DMD/No DMD) had significantly different satisfaction score for Side-effects as compared to oral
(fingolimod) DMD. This suggests that the satisfaction associated with effectiveness of treatments
were no different for those who were taking older injectable DMDs (interferons and glatiramer
acetate) as compared with those who were on newer oral DMDs. Overall satisfaction scores were
not significantly different for those who were on once a month infusion (natalizumab) or one a day
pill (fingolimod).

Significance
Understanding experiences, perception, and expectations of individuals with MS with
respect to DMDs has a key role in improving overall MS treatment management. Awareness of the
issues related to DMDs based on subjective (i.e. patients’ own) evaluation may help identify
advantages or obstacles that can interact with adherence to treatment plans involving DMDs. The
qualitative evaluation in this study indicates that individuals with MS have adapted themselves to
the current management of MS with DMDs. However individuals expect to see more benefits in
terms of convenience of administration, reduced dosage frequency, more clinical benefits in terms
of overall quality of life, myelin repair, and lastly a cure. Apart from Individual understanding of the
disease, beliefs and past experiences derive their expectations from the treatments they receive.
Knowledge gained for this study can be used to address patients’ concerns, improve patients’
understanding regarding DMDs, encourage involvement in decisions related to DMDs, and build
realistic expectations from the DMDs to optimize treatment selection.
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Participation of individuals with MS in treatment related decision making is always
encouraged and is also considered as the need for improving health outcomes. In order to select
the best possible DMD for individuals with MS, it is important for treating clinicians to understand
their preferences related to DMDs. However, it is not clear how individuals with MS perceive risks,
benefits, and other attributes related to convenience. This is the first study that evaluated
preferences for DMDs with respect to mode of administration, evidence on outcomes preferred in
a DMD, and flu-like symptoms along with benefit and risk related attributes. The results of this
study give us insights into how individuals with MS place higher importance on risks related
characteristics as opposed to the benefits provided by the DMDs. Newer DMDs and the ones that
are expected to be marketed in the future will have insufficient data related to benefits and risks.
Relative importance of risks associated with DMDs indicated by MS patients in this study supports
need for assessing how MS patients understand risks and uncertainties associated DMDs.
Treatment satisfaction is an important patient reported outcome. It is an important
indicator for evaluating acceptability of treatments or treatment related attributes for patients’
perspective. Disease conditions like MS, where a patient has to continue to take the treatment for
a longer duration, periodic objective evaluation with treatment satisfaction can be used to
determine adherence and persistence with the treatment. Satisfaction evaluation may allow
identification of individuals who would require a treatment change. The results of this study
suggest that patients’ overall satisfaction with MS treatment is mainly driven by treatment related
factors such as the type of DMD. One of the factors associated with switching or stopping DMDs is
the lack of treatment effectiveness. The results suggests that individuals who used different DMDs
in the past had lower satisfaction scores on Effectiveness and Side-effect scales, suggesting that the
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DMDs either were not clinically effective in those patients or could be due to nonadherence/switching. Negative association between satisfaction and clinical factors such as
relapses, disability status, and MS symptoms suggest that patients despite taking DMDs experience
relapses and progression of MS, a likely reason for patients to become non-adherent, switch, or
stop medication in the future.

Strengths
The strengths of the three studies conducted in this dissertation project include sound use
of qualitative and quantitative methods. Focus group discussion used in the first study is a highly
recommended and validated method for evaluation of subjective experiences, opinions, and
expectations regarding various aspects of healthcare. The uniqueness of the first study is that, as
per the author’s knowledge, this is one of first studies that explored aspects such as experiences,
perceptions, and expectations from the DMDs in MS. Preferences typically can be evaluated using
two different methods, revealed preference method and stated preference method, respectively
(Bridges, 2007). Revealed preferences of patients are evaluated when they are actually making a
treatment decision or have already made one. Administrative claims data for prescription filling is
one example where revealed preferences of patients are determined. However, such preferences
may be affected by extraneous factors such as patients’ socio-economic status, prescription
coverage, clinician preferences, etc and may not reflect patients’ true treatment preferences. On
the contrary, stated preference method focuses on eliciting preferences directly from patients
using survey questionnaire (Bridges, 2003). Also, the number of respondents in conjoint study was
high (n=897) as compared to other published studies utilizing conjoint analysis. This is one of few
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studies that evaluated treatment satisfaction among MS patients taking different DMDs using large,
national sample (n=951) with a response rate of approximately 25%.

Limitations
Limitations for individual studies have been discussed earlier at the end of respective study
chapters. This section provides overview of limitations for the entire project. This project involved
series of studies which were exploratory in nature. Moreover, the data collection process was
cross-sectional. Therefore causal relationship cannot be established.
In the qualitative study, the views of participants may be emergent in nature due to the
group dynamics and may not necessarily reflect participants ‘own opinions and expectations (Sim,
1998). The conclusions drawn from the focus group data can only indicate whether a particular
opinion was present or not. Assessment of relative magnitude of views, opinions, expectations,
and experiences cannot be established. Generalization of the interpretation of focus group data
can be debatable. Theoretical generalization of the results is relatively more acceptable than
practical generalization (Sim, 1998). Restricting sample to those who were taking a DMD at the
time of focus group discussion may not capture views of those who never used any DMD or were
not taking the DMD at the time of the study. All participants in focus group were White and the
views of MS patients from other racial origins may not overlap with the findings of this study.
Generally people who are more talkative, social, or interactive (extrovert) will be the ones who
participate in a focus group; therefore, some self-selection bias further limiting generalizability may
also be present.
Data collection for study 2 and 3 were done using web based survey. Majority of the
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respondents in these studies were college educated, therefore may limit the generalizability of the
studies 2 and 3, respectively. Conjoint analysis involves hypothetical choice tasks that patients
have to respond to. Although it is best suited method for eliciting patient preferences, it does not
necessarily mean that in the real life patients would make the same choices. Hypothetical nature
of conjoint tasks should be kept in perspective while interpreting the results of this study. Data
collection for conjoint analysis study was also cross-sectional.

Direction for the Future Research
Despite having quite a few DMD options around, selection of a DMD that is efficacious, safe,
and the one that is well tolerated by the individual patient is challenging. Treatment related
decisions in MS are likely to become even more complex with the possibility of increase in the
choices of DMDs that are more efficacious but more risky as well.
Success of DMDs mainly depends on patients taking it as they are supposed to, remaining
on the therapy for as long as they are supposed to, and by not dropping out. However the reasons
behind stopping or switching DMDs can be different for MS patients. In order to provide patient
centered care in MS, patient's perspective on variety of outcomes associated with DMDs needs to
be evaluated using qualitative and quantitative methods. This study collected data crosssectionally. The future research should focus on evaluation interrelation of factors such as
patients’ knowledge about disease and treatments, past experiences, treatment expectations,
benefit risk preferences, satisfaction with DMDs, quality of life, adherence, and persistence in a
single, possibly in a large multi-center study with prospective data collection.
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A comparison between physicians’ preferences and patients’ preferences for benefits and
risks associated with DMDs can provide differences in respective valuation of DMDs. Differences in
the benefit and risk valuation might provide information for developing better shared decision
making tools.
Conclusion
Individuals with MS understand the role of currently available DMDs in therapeutic
management of their condition and adapt themselves to available treatments; however, they have
greater expectations from emerging DMDs. DMDs with convenient routes of administration are
preferred by MS patients, but the side-effects and efficacy of these treatments are still the most
important factors. Patient satisfaction with the DMDs is associated with the type of currently used
DMD, relapses experienced, disabilility status, number of symptoms experienced, and the number
of DMDs used in the past. Routine evaluation of MS patients’ experiences, expectations, benefitrisk knowledge, benefit-risk preferences, and satisfaction with the current DMD can improve
understanding of unmet needs related to DMDs, and also inform developing effective therapeutic
management strategies to provide patient centered care.
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Appendix A: Focus Group - Script for Telephonic Invitation
Instructions: Telephone script – Contacting patients for the focus group interviews.
This brief recruitment script will be read to a convenience sample of approximately 35 - 40
multiple sclerosis (MS) patients who will be contacted to determine their willingness to participate
in the focus group discussion.
(Read)
Hello, my name is _________ (name of the research team member) and I am calling from
Drs. Gauri Pawar/Ludwig Gutmann/Tracy Weimer/John Brick’s office at the Neurology Clinic at
West Virginia University. Could I please speak with Mr. /Ms. /Mrs. (NAME OF THE PATIENT). We
would like to see if he/she/you would be willing to participate in a focus group discussion.
[TO BE READ TO THE PATIENT]
Researchers from the Neurology Clinic at the West Virginia University in collaboration with
West Virginia University School of Pharmacy are conducting a research study to determine patient
preferences for characteristics of disease modifying treatments used in multiple sclerosis, such as
treatment benefits, side effects, serious adverse events, and route of administration. This research
study is part of a doctoral (Ph.D.) research project, and has been acknowledged by the Institutional
Review Board of West Virginia University.
We are recruiting patients with multiple sclerosis, who have visited our neurology clinic in
the past one year to participate in the focus groups. The focus group will be a discussion involving
about 10 individuals with multiple sclerosis. Participants will be asked about their experiences with
disease modifying drugs (such as Avonex, Rebif, Copaxone, and Tysabri) used in the treatment of
multiple sclerosis, in addition to other aspects such as health related quality of life, treatment
satisfaction, health concerns, and expectations from newer disease modifying treatments for
multiple sclerosis. The information collected during the focus group discussions will be used to
develop a questionnaire. This questionnaire will then be used in a national survey to evaluate
patients’ preferences for disease modifying treatments.
Participation in this study is completely voluntary. Refusal to participate will not affect your
relationship and or the care you receive from the Neurology Clinic at the West Virginia University in
any way. All information collected from the focus group discussion will be kept confidential. You
do not have to answer any question that you don’t wish to. The information discussed during this
focus group will be analyzed as a whole, and no names will be used in the analysis of the discussion
content. If you agree to participate, you will receive a letter in the mail with study and contact
information from the investigators prior to the focus group.
Focus groups will be conducted in the – 4th week of February and 1st week of March (2010)
in a conference room in the Department of Pharmaceutical Systems and Policy at the West Virginia
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University School of Pharmacy. The focus group will last no longer than 2 hours. Upon completion
of the focus group, you will receive a $25 Walmart gift card as a token of appreciation for your time
and participation.
Would you be interested in participating in our focus group study?
Yes |____|

NO |____|

If NO, …..
We appreciate you taking the time to talk to us today. In case you change your mind and
are willing to participate in the focus group, please call us at 304-293-1639 at your earliest
convenience so that we can schedule you. [END CALL]
If YES, …..
In order to determine your eligibility for participating in the focus group, I would like to ask
you a few screening questions.
Focus Group Screening Questions
Q1. Are you 18 years of age or older?

Yes
Continue

Q2. Do you have a confirmed diagnosis of MS?

Continue

Q3. Have you visited the outpatient neurology clinic at WVU at least
once within the last one year?

Continue

Q4. Are you currently experiencing a relapse?

Stop –
Does not
qualify
Continue

Q5. Disease modifying drugs are the medicines that are used to
control the progression of MS and to prevent relapses associated with
MS. Have you ever used a disease modifying treatment (such as Rebif,
Avonex, Copaxone, Betaseron, Mitoxantrone or Tysabri) in the past to
treat your MS?
Q6. Are you currently taking a disease modifying treatment (such as
Rebif, Avonex, Copaxone, Betaseron, Mitoxantrone or Tysabri) to treat
your MS?

Continue

No
Stop –
Does not
qualify
Stop –
Does not
qualify
Stop –
Does not
qualify
Continue

Stop –
Does not
qualify

Stop –
Does not
qualify

If the individual is not eligible to participate in the focus group discussion: Thank you for your time.
Unfortunately, based on the answers you provided, you do not meet the criteria for participation in
the focus group discussion. Thank you once again for your interest and time and have a great day.
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If the individual is eligible to participate in the focus group discussion: Thank you. Based on the
answers you provided, you are eligible to participate in the focus group discussion. Would it be
alright with you if we go over the available times and dates now for you to attend the focus group
discussion?
If “No”: When can I contact you to go over the available times and dates for focus group
discussion? Confirm contact number.
If “Yes”: Discuss availability using following information
Which of the following dates and times are you available during the week of week of March 1st and
March 8th?
CHECK MARK AVAILABLE DATES AND TIMES BASED ON OPTIONS BELOW
Monday
1st Mar

Tuesday Wednesday Thursday
2nd Mar 3rd Mar
4th Mar

Friday
5th Mar

Saturday
6th Mar

Sunday
7th Mar

Monday
8th Mar

Tuesday Wednesday Thursday
9th Mar 10th Mar
11th Mar

Friday
12th Mar

Saturday
13th Mar

Sunday
14th Mar

10:00AM –
12:30 PM
12:30 PM –
3:00 PM
3:00AM – 5:30
PM
5:30AM – 8:00
PM

10:00AM –
12:30 PM
12:30 PM –
3:00 PM
3:00AM – 5:30
PM
5:30AM – 8:00
PM
Thank you for your interest in participating. We will contact you when a date and time has
been identified that is convenient to most of the individuals we are inviting. It is possible that the
date and time we select may not be convenient to you. We apologize if that happens and you
cannot participate. I would like to confirm your contact information (confirm name, email, and
address of the patient). Thank you and we will be contacting you with a scheduled focus group
discussion date and time in the next few weeks.
138

[Investigator contact information to be given only on the request of the participants and will
not be verbally communicated otherwise]
Investigator Contact Information:
Gauri Pawar, M.D. (Co-Investigator)
Associate Professor, Vice-Chair of Business Affairs and Compliance, Medical Director
Department of Neurology, School of Medicine
West Virginia University
Room 7500 HSS
P.O. Box 9180
Morgantown, WV 26506-9180
Phone: (304) 293-3527
Abhijeet Bhanegaonkar, MPH (Co-Investigator)
Doctoral Candidate
Department of Pharmaceutical Systems and Policy
West Virginia University School of Pharmacy
P.O. Box 9510
Morgantown WV 26506-9510
Phone: (304) 293-1442
S. Suresh Madhavan, MBA, Ph.D. (Principal Investigator)
Professor and Chair Department of Pharmaceutical Systems and Policy
West Virginia University School of Pharmacy
P.O. Box 9510
Morgantown WV 26506-9510
Phone: (304) 293-1652
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Appendix B: Focus Group - Invitation Letter

Dear Mr/Ms/Mrs (NAME OF THE PATIENT),
The Department of Neurology at West Virginia University School of Medicine and
Department of Pharmaceutical Systems and Policy at West Virginia University School of Pharmacy
are conducting a research study about multiple sclerosis to determine patients’ preferences
associated with disease modifying treatments. This research study is part of a doctoral (Ph.D.)
research project. This study has been acknowledged and approved by the Institutional Review
Board of West Virginia University.
Based on your willingness to participate in our focus group discussion, we have scheduled
you for the following date, time, and location:
DATE - DAY/DATE/MONTH (TBD)
TIME - TIME am/pm to TIME am/pm (TBD)
ADDRESS - ROOM # (TBD), Department of Pharmaceutical Systems and Policy, School of Pharmacy,
Health Science Center North, 1 Medical Center Drive, Morgantown WV 26506.
You will meet a designated person with a sign at the front entrance of the Family
Medicine/Dental Clinic of the Robert C. Byrd Health Sciences Center and he/she will guide you to
the conference room. If you are not able to attend the focus group on scheduled date/time for any
reason or if you experience a relapse between now and the focus group date, please let us know at
(304) 293-1639 at your earliest convenience to cancel your enrollment in the focus group
discussion.
Your participation in this study is completely voluntary, and refusal to participate will not
affect the service that you receive at Neurology Clinic at West Virginia University in any way. All
information collected during the focus group discussions will be kept confidential, and you do not
have to answer any question that you do not wish to answer. The information discussed during
this focus group will be analyzed as a whole, and no names will be used in the analysis of discussion
content. We will not ask any information that will reveal your identity as a participant. However, it
is possible that focus group participants may talk to each other and others about what will be
discussed during the focus group. If it happens we cannot bear any responsibility. You will receive
study and contact information from the investigators prior to the focus group.
The focus group discussion will take about 2 hours to complete. Upon completion of the
session, we will present you with a $25 Wal-Mart gift card as a token of our appreciation for your
time and participation.
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If you have any questions or need more information, please do not hesitate to contact, Dr.
Gauri Pawar at (304) 293-3527, Abhijeet Bhanegaonkar at (304) 293-1442, or Dr. Suresh Madhavan
at 304-293-1652.
Sincerely,
Gauri Pawar M.D.
Associate Professor
Department of Neurology
WVU School of Medicine

Abhijeet Bhanegaonkar MPH
Ph.D. Candidate
Department of Pharmaceutical
Systems and Policy
WVU School of Pharmacy
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S. Suresh Madhavan, MBA, Ph.D.
Professor and Chair
Department of Pharmaceutical
Systems and Policy
WVU School of Pharmacy

Appendix C: Focus Group - Moderator Script
The focus group time required: Approximately 2 hours
Moderator (script):
Hello, my name is Abhijeet Bhanegaonkar (you can call me AB), I am a doctoral candidate in
the Department of Pharmaceutical Systems and Policy at West Virginia University School of
Pharmacy. First, I would like to thank you all for taking time off from your busy schedules to come
here today and participate in this focus group discussion. For that we are very grateful to you.
This research is being conducted to determine patient preferences for characteristics of
disease modifying treatments used in multiple sclerosis such as Rebif, Avonex, Tysabri, etc. The
results of this study will improve our understanding about the disease modifying treatment
characteristics that are important to multiple sclerosis patients and what they expect from a future
disease modifying treatment.
Participation in this study is completely voluntary, and refusal to participate will not affect
your relationship and/or care that you receive at the Neurology Clinic at West Virginia University
School of Medicine in any way. The study has been acknowledged and approved by the
Institutional Review Board of West Virginia University.
Your involvement in this project will be kept as confidential as legally possible. The focus
group discussion will be audio-recorded so that the data can be transcribed; however, responses
will be kept confidential and individual names will not be associated with any reported data. We
will not ask any information that will reveal your identity as a participant. It is possible that focus
group participants may talk to each other or others about what will be discussed at this meeting. If
that happens we cannot bear any responsibility for that. You may refuse to answer any question,
or skip any question that you do not wish to answer. You may discontinue participation at any
time.
This [at this point, the moderator will provide participants a handout of list of referral
services] is the contact information for counseling facilities in the event that you experience any
emotional discomfort or stress due to this focus group discussion.
Before I begin with the discussion, I would like you to complete a very brief questionnaire.
That should take less than 5 minutes.
(After participants hand in the questionnaires, moderator will go over following guidelines
for the discussion)
Thank you, now we will begin the discussion. But, before we begin, I would like to list the
following guidelines to make our discussion more productive.
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•

During the discussion, we will not use names. Each participant will be given a number.
Please say your number loudly before you talk each time.

•

My role here is to ask questions and to listen. I will also take notes at times. I won’t be
actively participating in the conversation, only guiding it. I want you to feel free to talk
to the group and interact with each other and not just to me. I will ask questions about
your multiple sclerosis and treatment. There are no right or wrong answers. We are
interested in your experiences, opinions, and expectations associated with disease
modifying drugs. It is important that you relate your comments back to the questions. I
will move the discussion from one question to the next to try to keep us on track so that
we can finish on time.

•

Only one person should talk at a time. Please speak up since we are recording the
session and we don’t want to miss any of your comments. If you have trouble hearing
any of the comments, please let the group know.

•

There are just a few other things that I want you to know. I am not a medical doctor, so
I am not qualified to give out medical advice.

•

Your $25 payment will only be made at the completion of the focus group discussion.

•

Just so you know, the bathrooms are (directions will be pointed out). Once we start, we
will not be taking any breaks for the next 2 hours. If you need to go to the bathroom or
want to get up and get something more to drink please feel free to do so.

•

Do you have any questions before we begin the discussion?

(If patients have any additional questions, they will be answered. Once everyone is ready, we will
initiate the discussion using the following questions outlined below)
1. How long have you been living with multiple sclerosis?
2. How has your quality of life changed over the period of time (since the diagnosis of MS)?
What was it like before the diagnosis of MS and how is it now?
3. Can you tell me what disease modifying treatments you have taken in the past? Which
disease modifying treatment are you currently taking? (If patients are not taking the same
DMD now then ask the following question) What were some of the reasons for you to
switch/stop using your treatment with previous DMD/s?
4. How has your quality of life changed since you began taking DMD/s? How does the current
DMD you are taking affect your quality of life?
5. Overall, how would you describe your experience with the DMD (or DMDs) you had used in
the past?
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6. Overall, how would you describe your experience with the DMD that you are currently
using?
7. How has your past/current use of DMD (DMDs) helped alleviate your MS (in terms of
relapses, disease symptoms, functioning, daily activities of life, stress, etc)?
8. What are your minor (immediate) health concerns when it comes to treating your MS with
DMDs? (Such as side effects that affect your daily activities of life)
9. What are your major (long term) health concerns when it comes to treating your MS with
DMDs? (Such as adverse events including liver failure, progressive multifocal
leukoencephalopathy, leukemia etc.)
10. What are your financial concerns when it comes to treating your MS with DMDs? (Cost of
DMDs, co-pay, coverage of DMDs etc.)
11. What are your general ideas about the convenience of administration of the DMD (or
DMDs) you have previously used? (Self-injecting, using needles on a regular basis, visiting
hospitals each month to get infusion, etc.). Were these treatments easily accessible?
12. Would you consider yourself to be satisfied with the DMDs you have used to treat your MS?
Why or why not (Probe)?
13. Do you feel that you take your DMD as prescribed regularly? What factors contribute to
your being able to take it/not take it regularly?
14. What are your expectations from the future DMDs (oral therapies, combination therapies,
etc) that may come on the market? What characteristics would you like these new DMDs to
have?
15. Are there any final thoughts about your experiences with DMDs that you would like to
share?
Other questions may be asked as a follow-up to responses received from participants or if a new
line of inquiry is necessary.
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Appendix D: Focus Group - Sociodemographic Questionnaire
Participation in this study is completely voluntary, and refusal to participate will not affect
in any way your relationship and/or care that you receive from the Department of Neurology at the
West Virginia University. You may refuse to answer any question, or skip any question that you do
not wish to answer. You may discontinue participation at any time. The information provided by
you will be kept as confidential as legally possible.
INSTRUCTIONS: This questionnaire gathers basic information about you and your condition. Please
check mark (√) your responses.

1

Are you Male
Female

2

What is your age?
______

3

What is your marital status?
Single
Married
Divorced/separated
Widowed
Not married, living with a partner
Other (please Specify) ______________
Refuse to answer

4

Your ethnicity?
White/ Caucasian
Black/ African American
Hispanic/ Latino
Pacific Islander
Asian
American Indian/ Native Indian/ Alaskan Native
Other (please specify)_______________
Refuse to answer
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5

What is the highest level of education that you have completed?
Some high school or less
High school graduate or GED
Vocational college or some college
College degree
Graduate/professional degree
Other (please specify) _______________
Refuse to answer

6

What type of health insurance do you have?
Private health insurance
Government health insurance (such a Medicaid/ Medicaid)
Other (please specify) _________________
Uninsured
Refuse to answer

7

Which of the following best describes your employment status?
Employed/self-employed full time
Employed/self-employed part time
Retired
Homemaker
Student
Unable to work due MS
Unemployed
Seeking work
Other (please specify) ____________
Refuse to answer

8

What is your annual household income?
<$25,000
$25,000 - $49,999
$50,000 - $99,999
≥$100,000
Refuse to answer

9

How long ago were you diagnosed with MS?
______ Months/Year
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10

What was your year of diagnosis?
___________

11

What is your primary diagnosis?
Primary progressive MS
Secondary progressive MS
Relapsing remitting MS
Progressive relapsing MS
Don’t know

12

Does your health insurance cover at least some of the cost of your prescription
medications (like your disease modifying treatment)?
Yes
No

13

How long have you been taking ANY type of disease modifying drug for treating your
MS? (Specify number of years and months)
_____ Years _____ Months

14

Which of the following disease modifying drug/s you took in the PAST to treat your
MS? (you can check more than one box if you have taken more than one disease
modifying drugs in the past)
Avonex
Rebif
Betaseron

15

Copaxone
Novantrone
Tysabri

Don’t know

Which of the following disease modifying drug you are CURRENTLY using to treat your
MS?
Avonex
Rebif
Betaseron

Copaxone
Novantrone
Tysabri
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Don’t know

Appendix E: Focus Group - Acknowledgement

Dear Principal Investigator,
I acknowledge the receipt of a gift card in the amount of $25 for my participation in the
focus group discussion for the study titled “Patient Preferences for Benefits and Risks Associated
with Disease Modifying Drugs in Multiple Sclerosis”. I also understand that it is my responsibility to
verify if any action regarding the taxation of said gift card is needed.
Thank you,

Name: ____________________________________________

Signature __________________________________________

Date ______________________________________________
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Appendix F: Focus Group - Important Resources for Emotional Discomfort

Following is contact information for local counseling facilities in the event that you
experience any emotional discomfort as a result of the focus group discussion.

Morgantown Pastoral
Counseling
1062 Maple Dr #1
Morgantown, WV 26505
Phone – (304) 599-5751

Chestnut Ridge Hospital of
Morgantown WV
930 Chestnut Ridge Rd
Morgantown, WV 26505
Phone – (304) 598-6400

Fremouw Psychological Associates
1224 Pineview Dr #B
Morgantown, WV 26505
Phone – (304) 598-2300

Valley Healthcare System
301 Scott Ave
Morgantown, WV 26508
Phone – (304) 296-1731

Chestnut Ridge Counseling Services
Suite 116, 100 New Salem Road
Uniontown, PA 15401
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Appendix G: Web-based Survey – Email Invitation
(To be sent by Biogen Idec to MS patients in their registry)
Subject: Survey on Multiple Sclerosis - $25 for your participation
Dear Biogen Idec Registry Member:
Biogen Idec is partnering with the West Virginia University School of Pharmacy to conduct
an online research survey to better understand health related quality of life, work productivity,
treatment satisfaction, and preferences for different treatments used to treat multiple sclerosis.
This research study is part of a doctoral (Ph.D.) research project and is sponsored by Biogen
Idec Inc. This research survey is anonymous and the information provided will be kept as
confidential as legally possible. The survey results will be grouped together with others completing
the survey. This research study has been acknowledged by the Institutional Review Board of West
Virginia University. You must be 18 years of age or older to participate in this research survey.
Participation in this survey is entirely voluntary. However, your participation in this survey
is vital to make this research truly meaningful. The completion of this survey will take
approximately 20 minutes. Please help us by completing the entire survey.
Upon survey completion from eligible respondents, researchers at West Virginia University
will send you a $25 gift card. Please respond quickly - this survey will only be open for a limited
time.
[SURVEY URL]
We THANK YOU in advance, for your time and your contributions to a greater
understanding of the health matters of individuals with MS. If you have any questions regarding
the survey or need more information about the study, please email the research team members Dr.
S. Suresh Madhavan (PI) on (304) 293-1652 or Abhijeet Bhanegaonkar on (404) 434-4575 or email
us at MSstudy@hsc.wvu.edu.
Have a great day!
Sincerely,
Your Biogen Idec team
NOTE: You must complete the three questions on the eligibility screen before completing this
survey. Completing the eligibility screen alone does NOT qualify you for the $25 gift card.
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Appendix H. Web-Based Survey – Survey Questionnaire
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Treatment Preference in Multiple Sclerosis Survey

We appreciate your participation this research survey.
[SCREENING QUESTIONS]
We appreciate your interest in this research survey.
Please answer the following THREE screening questions before moving on to the actual survey.
Screening Questions
Q1. Do you have a confirmed diagnosis of MS?
Q2. Are you 18 years of age or older?
Q3. Are you a resident of United States
If NO ≥1 then participants do not qualify. Thank and terminate.
If YES=3 then participants qualify. Proceed to the survey.
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Yes
1
1
1

No
2
2
2

ABOUT YOUR MS…
4. When were you first diagnosed with MS?
Month _________ [Provide dropdown]
Year _________ [Provide dropdown]
5. What type of MS do you have?
1
2
3
4

Relapsing remitting MS
Primary progressive MS
Secondary progressive MS
Progressive relapsing MS

6. Are you currently experiencing a relapse?
1
2

Yes
No
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IF Q6=Yes
7. Which of the following MS categories best describes your illness before this most recent
relapse?
Please select category that best describes your answer.

0

0

1

1

2

2

3

3

4

4

5

5

6

6

7

7

8

8

Normal: I may have some mild symptoms, mostly sensory due to MS but they do
not limit my activity. If I do have an attack, I return to normal when the attack has
passed.
Mild Disability: I have some noticeable symptoms from my MS but they are minor
and have only a small effect on my lifestyle.
Moderate Disability: I don’t have any limitations in my walking ability. However, I
do have significant problems due to MS that limit daily activities in other ways.
Gait Disability: MS does interfere with my activities, especially my walking. I can
work a full day, but athletic or physically demanding activities are more difficult
than they used to be. I usually don't need a cane or other assistance to walk, but I
might need some assistance during an attack.
Early Cane: I use a cane or a single crutch or some other form of support (such as
touching a wall or leaning on someone’s arm) for walking all the time or part of the
time, especially when walking outside. I think I can walk 25 feet in 20 seconds
without a cane or crutch. I always need some assistance (cane or crutch) if I want
to walk as far as 3 blocks.
Late Cane: To be able to walk 25 feet, I have to have a cane, crutch or someone to
hold onto. I can get around the house or other buildings by holding onto furniture
or touching the walls for support. I may use a scooter or wheelchair if I want to go
greater distances.
Bilateral Support: To be able to walk as far as 25 feet I must have 2 canes or
crutches or a walker. I may use a scooter or wheelchair for longer distances.
Wheelchair / Scooter: My main form of mobility is a wheelchair. I may be able to
stand and/or take one or two steps, but I can't walk 25 feet, even with crutches or
a walker.
Bedridden: Unable to sit in a wheelchair for more than one hour.
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IF Q6=Yes
8. Which of the following MS categories best describes your current illness?
Please select a category that best describes your situation.

0

0

1

1

2

2

3

3

4

4

5

5

6

6

7

7

8

8

Normal: I may have some mild symptoms, mostly sensory due to MS but they do
not limit my activity. If I do have an attack, I return to normal when the attack has
passed.
Mild Disability: I have some noticeable symptoms from my MS but they are minor
and have only a small effect on my lifestyle.
Moderate Disability: I don’t have any limitations in my walking ability. However, I
do have significant problems due to MS that limit daily activities in other ways.
Gait Disability: MS does interfere with my activities, especially my walking. I can
work a full day, but athletic or physically demanding activities are more difficult
than they used to be. I usually don't need a cane or other assistance to walk, but I
might need some assistance during an attack.
Early Cane: I use a cane or a single crutch or some other form of support (such as
touching a wall or leaning on someone’s arm) for walking all the time or part of the
time, especially when walking outside. I think I can walk 25 feet in 20 seconds
without a cane or crutch. I always need some assistance (cane or crutch) if I want
to walk as far as 3 blocks.
Late Cane: To be able to walk 25 feet, I have to have a cane, crutch or someone to
hold onto. I can get around the house or other buildings by holding onto furniture
or touching the walls for support. I may use a scooter or wheelchair if I want to go
greater distances.
Bilateral Support: To be able to walk as far as 25 feet I must have 2 canes or
crutches or a walker. I may use a scooter or wheelchair for longer distances.
Wheelchair / Scooter: My main form of mobility is a wheelchair. I may be able to
stand and/or take one or two steps, but I can't walk 25 feet, even with crutches or
a walker.
Bedridden: Unable to sit in a wheelchair for more than one hour.
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9. Which of the following disease modifying drugs you are CURRENTLY using to treat your MS?
1
2
3
4
5
6
7
8
9
10

Avonex®
Betaseron®
Copaxone®
Extavia®
Gilenya®
Novantrone®
Rebif®
Tysabri®
Drug under clinical trial
None of the above

10. Since when have you been taking ________ (Q9=Current DMD) to treat your MS?
Year __________ [Provide dropdown]
Month__________ [Provide dropdown]

IF Q9≠None of the above
11. Which of the following disease modifying drugs did you take in the past before starting on
___________ (Q9=Current DMD)? (Check more than one box if you took more than one disease
modifying drugs in the past)
1
2
3
4
5
6
7
8
9
10
11

Avonex®
Betaseron®
Copaxone®
Extavia®
Gilenya®
Novantrone®
Rebif®
Tysabri®
Drug under clinical trial
Other (Please specify) ________
None of the above
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IF Q9=None of the above
12. Which of the following disease modifying drugs have you taken in the PAST to treat your
MS? (Check more than one box if you took more than one disease modifying drugs in the past
1
2
3
4
5
6
7
8
9
10
11

Avonex®
Betaseron®
Copaxone®
Extavia®
Gilenya®
Novantrone®
Rebif®
Tysabri®
Drug under clinical trial
Other (Please specify) ________
None of the above

13. What type of health insurance do you have?
1
2
3
4
5

Private health insurance
Medicaid
Medicare
Uninsured
Other (Please specify) _________

14. Which of the following statements best describes your situation?
1
My health insurance covers ALL of the cost of my MS medicines
2
My health insurance covers MOST of the cost of my MS medicines
3
My health insurance covers SOME of the cost of my MS medicines
4
My health insurance DOES NOT COVER any of the costs of my MS medicines
5
I get my MS medicines through a SUPPORT PROGRAM of a Pharmaceutical company as I
have no health insurance
6
I DO NOT TAKE MY MS medicines as I have no health insurance to pay for them
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15. How many MS relapses you have experienced in the last 12 months?
Select a number _______________ [Provide a dropdown]

16. In the last 12 months, how many times have you seen a primary care physician for your MS?
Select a number _______________[Provide a dropdown]

17. In the last 12 months, how many times have you seen a neurologist for your MS?
Select a number _______________[Provide a dropdown]
18. Do you have a family history of MS in blood relatives?
1
2

Yes
No

IF Q18 = Yes then show Q19.
19. Specify the relation (Brother, Sister, etc.)
_______________
IF Q18 = Yes then show Q20.
20. Is the relative mentioned above a twin?
1
2
3

Not a twin
Fraternal
Identical

21. Are you a twin?
1
2
3

Not a twin
Fraternal
Identical
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22. Has a doctor ever told you that you have or treated you for any of the following conditions in
the past? (Please select all that applies)
Hypertension
Heart disease
Cataracts
peptic ulcer disease
Inflammatory bowel
disease
rheumatoid arthritis
Arthritis
knee⁄hip replacements
bipolar disorder
Hearing loss
,

Cancer (Specify) ______
Peripheral vascular disease
Glaucoma
Liver disease
Autoimmune thyroid
disease
Sjogren’s disease
Fibromyalgia
Depression
Schizophrenia
Hepatitis

Diabetes
Lung disease
Uveitis
Irritable bowel syndrome
Systemic lupus
erythematosus
Kidney disease
anemia
Anxiety
Seizures
Other (Specify) ______

23. During the last one month, have you experienced any of the following symptoms as a result
of your MS? (Please select all the symptoms that you experienced)
Bowel problems
Sexual dysfunction
Fatigue
Numbness, Tingling, Burning Sensations
Balance/Coordination
Dizziness
Chronic pain
Other (Please specify) _____________

Memory and attention problems
Depression (feeling down) or mood
Vision problems
Slurred speech
Problems with swallowing
Tremor
Spasticity (muscle stiffness)
Problem in walking
Bladder problems
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FEATURES OF MS TREATMENTS
Next few screens will describe features of the commonly used MS medications. Please read the
following description carefully. This information will help you in answering questions later in this
survey.
Treatment Administration: MS treatments vary by their mode of administration. Three most
common ways to take MS medicines are pill at home, injection at home, or infusion at the clinic.
24. For my MS I take…
1
2
3

Pill at home
Injection at home
Infusion at clinic

Evidence on Outcomes: The longer a treatment is on the market, the more the information is
available about its safety and benefits. Therefore our understanding of the benefits and safety
outcomes of these treatments improve with the passage of time. Later in the survey you will be
asked to consider different MS treatments with evidence on outcomes gathered after: 5 years of
research, 10 years of research, or 15 years of research.
25. How important is evidence on outcomes to you?
1
2
3

Extremely
Somewhat
Not at all

Number of Relapses: Current MS treatments reduce occurrence of relapses. An average MS
patient experiences 6 relapses over 5 years. Assume that you will have 6 relapses over the next 5
years with your current treatment. Later in the survey you will be asked to consider different MS
treatments with 0 Relapse, 3 Relapses, or 6 Relapses within next 5 years.
26. How concerned are you about your future MS relapses?
1
2
3

Extremely
Somewhat
Not at all
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Delaying Progression of MS: MS affects physical functioning (example: walking ability) and
neurological functioning (example: memory, eyesight) and causes disability over time. MS
treatments slow down disability progression.
Previously you indicated your current level of functioning as:
[PUT THE LEVEL (n) OF DISABILITY AS INDICATED FROM Q.7 or 8]
If your illness worsens, you are most likely to experience a level of functioning best described as:
[PUT THE NEXT LEVEL (n+1) OF AS DISABILITY FROM Q.7 or 8]
An average patient not taking any MS medicine advances to higher level of illness category in 5 or
more years.
Later in this survey you will be asked to consider different treatments delaying progression of MS
by 5 Years, 10 Years, or 15 Years.
27. How satisfied are you with your current treatment’s ability to delay progression of your MS?
1
2
3

Extremely
Somewhat
Not at all

Severe Disability or Death from Progressive Multifocal Leukoencephalopathy (PML): PML is a
rare but serious viral infection of the brain that can cause death or severe disability. Some MS
treatments increase the chance of PML. Later in the survey you will be asked you to consider MS
treatments with the following chances of death or severe disability associated with PML within the
next 5 years: None, 4 patients out of 1,000, or 8 patients out of 1,000.
28. If a MS treatment caused PML in 5 patients out of 1000, how concerned would you be to take
that medicine?
1
2
3

Extremely
Somewhat
Not at all
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Severe Liver Dysfunction within 5 Years: MS treatments can affect liver function which may cause
jaundice, nausea, fatigue, and vomiting. Later in the survey you will be asked to consider different
treatments with severe liver dysfunction in the next 5 years in none, 10 patients out of 1000, or 20
patients out of 1000.
29. If a MS medicine caused severe liver dysfunction in 15 patients out of 1000, how worried
would you be to take that medicine?
1
2
3

Extremely
Somewhat
Not at all

Flu-like Symptoms: MS patients frequently experience flu-like symptoms after taking MS
medications. These symptoms may include fever, chills, sweating, muscle aches, and fatigue. Later
in this survey you will be asked to consider different MS treatments with none, mild, or severe flu
like symptoms.
30. Have you ever experienced flu-like symptoms with your MS medicine?
1
2

Yes
No
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Below is an example of the treatment option. In this example, Medicine A is preferred to
Medicine B (as shown by the RED ARROW).
You will see on the similar choice questions in the next few screens. Choose your preferred
Medicine by clicking the box at the bottom of the screen
EXAMPLE OF CHOICE QUESITON
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Choice Question 31
(Block 1 Run 1)

MEDICINE FEATURE

MEDICINE A

MEDICINE B

Treatment administration

Pill at home0

Injection at home1

Evidence on outcomes

10 years of research1

10 years of research1

Number of relapses within 5 years

6 relapses2

0 relapses0

Delaying progression of MS

5 years of delay0

15 years of delay2

Severe disability or death from PML
within 5 years

None0

4 patients out of 10001

Severe liver dysfunction within 5 years

20 patients out of
10002

10 patients out of 10001

Flu-like symptoms

Mild1

None0





Which medicine
would you choose?
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Choice Question 32
(Block 1 Run 2)

MEDICINE FEATURE

MEDICINE A

MEDICINE B

Treatment administration

Pill at home0

Infusion at the
clinic2

Evidence on outcomes

15 years of research2

15 years of
research2

Number of relapses within 5 years

6 relapses2

6 relapses2

Delaying progression of MS

15 years of delay2

15 years of delay2

Severe disability or death from PML
within 5 years

None0

None0

Severe liver dysfunction within 5 years

20 patients out of
10002

10 patients out of
10001

Flu-like symptoms

None0

Severe2

Which medicine
would you choose?
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Choice Question 33
(Block 1 Run 3)

MEDICINE FEATURE

MEDICINE A

MEDICINE B

Treatment administration

Infusion at the clinic2

Infusion at the clinic2

Evidence on outcomes

10 years of research1

10 years of research1

Number of relapses within 5 years

3 relapses1

6 relapses2

Delaying progression of MS

15 years of delay2

15 years of delay2

Severe disability or death from PML
within 5 years

None0

8 patients out of
10002

Severe liver dysfunction within 5 years

10 patients out of
10001

None0

Flu-like symptoms

Severe2

None0

Which medicine
would you choose?
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Choice Question 34
(Block 1 Run 4)

MEDICINE FEATURE

MEDICINE A

MEDICINE B

Treatment administration

Injection at home1

Injection at home1

Evidence on outcomes

5 years of research 0

15 years of research2

Number of relapses within 5 years

0 relapses0

6 relapses2

Delaying progression of MS

10 years of delay1

10 years of delay1

Severe disability or death from PML
within 5 years

None0

8 patients out of
10002

Severe liver dysfunction within 5 years

20 patients out of
10002

10 patients out of
10001

Flu-like symptoms

Mild1

Mild1

Which medicine
would you choose?
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Choice Question 35
(Block 1 Run 5)

MEDICINE FEATURE

MEDICINE A

MEDICINE B

Treatment administration

Infusion at the clinic2

Injection at home1

Evidence on outcomes

15 years of research2

10 years of
research1

Number of relapses within 5 years

6 relapses2

0 relapse0

Delaying progression of MS

15 years of delay2

10 years of delay1

Severe disability or death from PML
within 5 years

None0

8 patients out of
10002

Severe liver dysfunction within 5 years

10 patients out of
10001

20 patients out of
10002

Flu-like symptoms

None0

Severe2

Which medicine
would you choose?
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Choice Question 36
(Block 1 Run 6)

MEDICINE FEATURE

MEDICINE A

MEDICINE B

Treatment administration

Injection at home1

Pill at home0

Evidence on outcomes

5 years of research0

5 years of research0

Number of relapses within 5 years

6 relapses2

6 relapses2

Delaying progression of MS

5 years of delay0

15 years of delay2

Severe disability or death from PML
within 5 years

4 patients out of
10001

4 patients out of
10001

Severe liver dysfunction within 5 years

10 patients out of
10001

20 patients out of
10002

Flu-like symptoms

Severe2

Mild1

Which medicine
would you choose?
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Choice Question 37
(Block 1 Run 7)

MEDICINE FEATURE

MEDICINE A

MEDICINE B

Treatment administration

Injection at home1

Pill at home0

Evidence on outcomes

15 years of research2

10 years of
research1

Number of relapses within 5 years

0 relapses0

0 relapses0

Delaying progression of MS

15 years of delay2

15 years of delay2

Severe disability or death from PML
within 5 years

None0

4 patients out of
10001

Severe liver dysfunction within 5 years

None0

10 patients out of
10001

Flu-like symptoms

None0

None0

Which medicine
would you choose?



170



Choice Question 38
(Block 1 Run 8)

MEDICINE FEATURE

MEDICINE A

MEDICINE B

Treatment administration

Infusion at the
clinic2

Injection at home1

Evidence on outcomes

15 years of
research2

15 years of research2

Number of relapses within 5 years

3 relapses1

6 relapses2

Delaying progression of MS

10 years of delay1

15 years of delay2

Severe disability or death from PML within 5
years

8 patients out of
10002

4 patients out of 10001

Severe liver dysfunction within 5 years

None0

None0

Flu-like symptoms

Mild1

None0

Which medicine
would you choose?
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Choice Question 39
(Block 1 Run 9)

MEDICINE FEATURE

MEDICINE A

MEDICINE B

Treatment administration

Infusion at the clinic2

Pill at home0

Evidence on outcomes

10 years of research1

5 years of research0

Number of relapses within 5 years

0 relapse0

6 relapses2

Delaying progression of MS

15 years of delay2

15 years of delay2

Severe disability or death from PML
within 5 years

4 patients out of
10001

4 patients out of
10001

Severe liver dysfunction within 5 years

None0

None0

Flu-like symptoms

Mild1

Severe2

Which medicine
would you choose?
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Choice Question 40
(Block 1 Run 7)
(Repeat Question#7)

MEDICINE FEATURE

MEDICINE A

MEDICINE B

Treatment administration

Injection at home1

Pill at home0

Evidence on outcomes

15 years of research2

10 years of research1

Number of relapses within 5 years

0 relapse0

0 relapse0

Delaying progression of MS

15 years of delay2

15 years of delay2

Severe disability or death from PML
within 5 years

None0

4 patients out of
10001

Severe liver dysfunction within 5 years

None0

10 patients out of
10001

Flu-like symptoms

None0

None0

Which medicine
would you choose?
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ABOUT YOUR QUALITY OF LIFE…
The following questions ask for your views on the impact of MS on your day-to-day life during the
past 2 weeks. For each statement, please circle the one number that best describes your situation.
Please answer all questions.
Not at all
A little
Moderately
Quite a bit
Extremely
In the past 2 weeks,
how much has your MS
limited your ability to …
41. Do physically
1
2
3
4
5
demanding tasks?
42. Grip things tightly
1
2
3
4
5
(e.g. turning on taps)?
1
2
3
4
5
43. Carry things?
In the past 2 weeks,
how much have you
been bothered by …
44. Problems with your
balance?
45. Difficulties moving
about indoors?
46. Being clumsy?

Not at all

A little

Moderately

Quite a bit

Extremely

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

47. Stiffness?

1

2

3

4

5

48. Heavy arms and/or
legs?
49. Tremor of your arms
or legs?
50. Spasms in your
limbs?
51. Your body not doing
what you want it to do?
52. Having to depend on
others to do things for
you?
53. Limitations in your
social and leisure
activities at home?
54. Being stuck at home
more than you would
like to be?

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5
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In the past 2 weeks,
how much have you
been bothered by …

Not at all

A little

Moderately

Quite a
bit

Extremely

55. Difficulties using
your hands in everyday
tasks?
56. Having to cut down
the amount of time you
spent on work or other
daily activities?
57. Problems using
transport (e.g. car, bus,
train, taxi, etc.)?
58. Taking longer to do
things?
59. Difficulty doing
things spontaneously
(e.g. going out on the
spur of the moment)?
60. Needing to go to the
toilet urgently?
61. Feeling unwell?

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

62. Problems sleeping?

1

2

3

4

5

63. Feeling mentally
fatigued?
64. Worries related to
your MS?
65. Feeling anxious or
tense?
66. Feeling irritable,
impatient or shorttempered?
67. Problems
concentrating?
68. Lack of confidence?

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

69. Feeling depressed?

1

2

3

4

5
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ABOUT YOUR HEALTH…
This section of the survey asks you for your views about your health. This information will help
us understand how you feel and how well you are able to do your usual activities.
70. In general, would you say your health is:
Excellent
1

Very good
2

Good

Fair

3

Poor

4

5

71. The following questions are about activities you might do during a typical day. Does your
health now limit you in these activities? If so, how much?
Yes,
limited
a lot

Yes,
limited
a little

No, not
limited
at all

a Moderate activities, such as moving a table, pushing
a vacuum cleaner, bowling, or playing golf..............................

1.............

2 .............

3

b Climbing several flights of stairs...............................................

1.............

2 .............

3
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72. During the past 4 weeks, how much of the time have you had any of the following
problems with your work or other regular daily activities as a result of your physical
health?

All of
the time
a
b

Most of
the time

Some of
the time

A little of
the time

None of
the time

Accomplished less than you
would like ......................................

1 .............

2 .............

3 ..............

4 ............

5

Were limited in the kind of
work or other activities.................

1 .............

2 .............

3 ..............

4 ............

5

73. During the past 4 weeks, how much of the time have you had any of the following
problems with your work or other regular daily activities as a result of any emotional
problems (such as feeling depressed or anxious)?
All of
the time
a
b

Most of
the time

Some of
the time

A little of
the time

None of
the time

Accomplished less than you
would like ......................................

1 .............

2 .............

3 ..............

4 ............

5

Did work or other activities
less carefully than usual................

1 .............

2 .............

3 ..............

4 ............

5

74. During the past 4 weeks, how much did pain interfere with your normal work (including
both work outside the home and housework)?
Not at all
1

A little bit
2

Moderately
3

177

Quite a bit
4

Extremely
5

75. These questions are about how you feel and how things have been with you during the
past 4 weeks. For each question, please give the one answer that comes closest to the
way you have been feeling. How much of the time during the past 4 weeks…
All of
the time
a

Most of
the time

Some of
the time

A little of
the time

None of
the time

Have you felt calm and
peaceful? ......................................
......................................................

1 ............. ....................
5

2 .............

3 .............

4

b

Did you have a lot of energy? .......
......................................................

1 ............. ....................
5

2 .............

3 .............

4

c

Have you felt downhearted
and depressed?.............................
......................................................

1 ............. ....................
5

2 .............

3 .............

4

All of
the time
1

Most of
the time
2

Some of
the time
3

A little of
the time
4

None of
the time
5

76. During the past 4 weeks, how much of the time has your physical health or emotional
problems interfered with your social activities (like visiting with friends, relatives, etc.)?
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ABOUT SATISFACTION WITH YOUR MS TREATMENT…
Please take some time to think about your level of satisfaction or dissatisfaction with the MS
treatment you are currently taking. We are interested in your evaluation of the effectiveness,
side effects, and convenience of the MS treatment over the past two to three weeks, or since
you last used it. For each question, please place a single check mark next to the response that
most closely corresponds to your own experiences.
77. How satisfied or dissatisfied are you with the ability of the MS treatment to prevent or
treat the condition?
1 Extremely Dissatisfied
2 Very Dissatisfied
3 Dissatisfied
4 Somewhat Satisfied
5 Satisfied
6 Very Satisfied
7 Extremely Satisfied
78. How satisfied or dissatisfied are you with the way the MS treatment relieves symptoms?
1 Extremely Dissatisfied
2 Very Dissatisfied
3 Dissatisfied
4 Somewhat Satisfied
5 Satisfied
6 Very Satisfied
7 Extremely Satisfied
79. As a result of taking your MS treatment, do you experience any side effects at all?
1 Yes
0 No
80. How dissatisfied are you by side effects that interfere with your physical health and ability
to function (e.g. strength, energy levels)?
1 Extremely Dissatisfied
2 Very Dissatisfied
3 Somewhat Dissatisfied
4 Slightly Dissatisfied
5 Not at all Dissatisfied
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81. How dissatisfied are you by side effects that interfere with your mental function (e.g.
ability to think clearly, stay awake)?
1 Extremely Dissatisfied
2 Very Dissatisfied
3 Somewhat Dissatisfied
4 Slightly Dissatisfied
5 Not at all Dissatisfied
82. How dissatisfied are you by side effects that interfere with your mood or emotions (e.g.
anxiety/fear, sadness, irritation/anger)?
1 Extremely Dissatisfied
2 Very Dissatisfied
3 Somewhat Dissatisfied
4 Slightly Dissatisfied
5 Not at all Dissatisfied
83. How satisfied or dissatisfied are you with how easy the MS treatment is to use?
1 Extremely Dissatisfied
2 Very Dissatisfied
3 Dissatisfied
4 Somewhat Satisfied
5 Satisfied
6 Very Satisfied
7 Extremely Satisfied
84. How satisfied or dissatisfied are you with how easy it is to plan when you will use the MS
treatment each time?
1 Extremely Dissatisfied
2 Very Dissatisfied
3 Dissatisfied
4 Somewhat Satisfied
5 Satisfied
6 Very Satisfied
7 Extremely Satisfied
85. How satisfied or dissatisfied are you by how often you are expected to use/take the MS
treatment?
1 Extremely Dissatisfied
2 Very Dissatisfied
3 Dissatisfied
4 Somewhat Satisfied
5 Satisfied
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6
7

Very Satisfied
Extremely Satisfied

86. How satisfied are you that the good things about your MS treatment outweigh the bad
things?
1 Extremely Dissatisfied
2 Very Dissatisfied
3 Dissatisfied
4 Somewhat Satisfied
5 Satisfied
6 Very Satisfied
7 Extremely Satisfied
87. Taking all things into account, how satisfied or dissatisfied are you with your MS
treatment?
1 Extremely Dissatisfied
2 Very Dissatisfied
3 Dissatisfied
4 Somewhat Satisfied
5 Satisfied
6 Very Satisfied
7 Extremely Satisfied

WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT (WPAI)
Time at Work: The following questions ask you about the effect of your MS on your ability to
work and perform regular daily activities.
88. Are you currently employed (working for pay)?
0 NO
1 YES
[IF NO, CHECK “NO” AND SKIP TO QUESTION 88.]
The next questions are about the past seven days, not including today.
89.
During the past seven days, how many hours did you miss from work because of
PROBLEMS ASSOCIATED WITH YOUR MS? Include hours you missed on sick days, times you
went in late, left early, etc., because of your health problems. Do not include time you missed
to participate in this study.
_____

HOURS

[PROVIDE A DROPDOWN BOX]
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90. During the past seven days, how many hours did you miss from work because of any other
reason, such as vacation, holidays; time off to participate in this study?
_____

HOURS

[PROVIDE A DROPDOWN BOX]
91. During the past seven days, how many hours did you actually work?
_____

HOURS

[PROVIDE A DROPDOWN BOX]
[IF “0”, SKIP TO QUESTION 88]

When answering the next question, please think about days you were limited in the
amount or kind of work you could do, days you accomplished less than you would like,
or days you could not do your work as carefully as usual. Choose by checking a box.
If symptoms of MS affected your work only a little, choose a low number. Choose a high
number if health problems affected your work a great deal.
92. During the past seven days, how much did your MS affect your productivity while you
were working?
Consider only how much your MS affected
productivity while you were working.
My MS had no
effect on my
work

0

1

2

3

4

5

6

7

8

9

10

0

1

2

3

4

5

6

7

8

9

10

My MS
completely
prevented me
from working

When answering the next question, by regular activities, we mean the usual activities
you do, such as work around the house, shopping, childcare, exercising, studying, etc.
93. During the past seven days, how much did your MS affect your ability to do your regular
daily activities, other than work at a job?
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Think about times you were limited in the amount or kind of activities you could do and
times you accomplished less than you would like.
If MS affected your activities only a little, choose a low number. Choose a high number if
health problems affected your activities a great deal.
Consider only how much MS affected your ability
to do your regular daily activities, other than work at a job.

My MS had no
effect on my
daily activities

0

1

2

3

4

5

6

7

8

9

10

0

1

2

3

4

5

6

7

8

9

10

A FEW QUESTIONS ABOUT YOURSELF...
94. Your gender is…
1 Male
2 Female
95. You were born in…
_____ Year ____ Month
96. Your marital status is…
1 Single
2 Married
3 Divorced/separated
4 Widowed
5 Not married, living with a partner

97. Your race is
1 White/Caucasian
2 Black/ African American
3 Hispanic/ Latino
4 Asian
5 Others

98. Your educational qualification?
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My MS
completely
prevented me
from doing
my daily
activities

1
2
3
4
5

High school or Less than High School
Some college, but no degree
Bachelor’s degree (BA, BS, etc.)
Master’s degree (MA, MS, etc.)
Doctoral or Professional degree (PhD, MD, Pharm D, etc.)

99. What is your current employment status?
1
2
3
4
5
6
7

Employed full time
Employed part time
Homemaker
Student
Retired
Unable to work due to MS
Unemployed

100. What is your annual household income?
1
2
3
4
5

<$25,000
$25,001-$50,000
$50,001-$75,000
$75,001-$100,000
>$100,000

101. What type of health insurance do you have?
1
2
3
4
5

Private health insurance
Medicaid
Medicare
Uninsured
Other (please specify) _________________

102. Your Height is… ________
103. Your Weight is …________
104. Are you a current smoker?
0 No
1 Yes
105. Which State do you currently reside in? _____________
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Appendix I: Web-Based Survey – First Reminder

Dear (Name of the recipient),
You are receiving this email because you have previously expressed interest to Biogen Idec in
receiving emails regarding products, services, and programs that may be of interest to you.
Biogen Idec has provided funding for our multiple sclerosis study that is part of a doctoral
(Ph.D.) research project with The School of Medicine and the School of Pharmacy at West
Virginia University, and the research includes an on-line survey designed to gain a better
understanding of health-related quality of life, work productivity, treatment satisfaction, and
treatment preferences among people living with multiple sclerosis. This study has been
acknowledged by the Institutional Review Board of West Virginia University, and we are
reaching out to you to invite you to participate in the study by completing the on-line survey
linked to this email.
Participation in this survey is entirely voluntary and any information you choose to provide will
be kept confidential. All results will be presented grouped together with others completing the
survey so that no individual responses are shared. The survey does not require any information
that will reveal your identity as a participant and you do not need to answer any questions with
which you are not comfortable. Refusal to participate or withdrawal from the study will in no
way affect your future care, however, your participation is extremely valuable because your
responses and opinions are necessary to make the results of this study truly meaningful. Please
help us by completing the survey. Please click on the link below to access the survey.
Take the Survey: https://wvusop.us2.qualtrics.com/SE/?SID=SV_bdA6SMdCZlXQMa8&id=22222
The completion of this survey will take approximately 15-20 minutes. As a token of our
appreciation for your participation, a $25 gift card can be mailed to you after fully completing
the survey. Individuals completing the survey will be requested to provide their name and
address at the end of the survey for the sole purpose of mailing the $25 gift card. You may elect
not to share your mailing address if you do not wish to share any personal information, but we
will then be unable to send a gift card for your participation.
We THANK YOU in advance, for your time and your contributions to a greater understanding of
the health matters of individuals with MS. If you have any questions regarding the survey or
need more information, please email us at MSstudy@hsc.wvu.edu or call us at (404) 434-4575.
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Take the Survey:https://wvusop.us2.qualtrics.com/SE/?SID=SV_bdA6SMdCZlXQMa8&id=22222
Sincerely,
Abhijeet Bhanegaonkar MPH
Ph.D. Candidate
Department of Pharmaceutical Systems and Policy
WVU School of Pharmacy
Morgantown, WV - 26506

S. Suresh Madhavan, MBA, Ph.D.
Professor and Chair
Department of Pharmaceutical Systems
and Policy
WVU School of Pharmacy
Morgantown, WV - 26506

Do not reply to this message. This is a notification-only mailbox that cannot accept incoming email.
You received this e-mail because you indicated that you wanted to receive information from
Biogen Idec and Elan Pharmaceuticals, Inc., the sponsors of MS ActiveSource. Your name,
address, and other personally identifiable information you provide will not be sold to any third
party. If you do not wish to receive information from MS ActiveSource, please unsubscribe.
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Appendix J: Web
Web-Based Survey – Thank You Letter
Date

Dear Participant,
We want to THANK YOU for your recent participation in our on-line
line Multiple Sclerosis
(MS) study survey conducted by WVU School of Pharmacy with a dissertation grant from Biogen
Idec.. Knowledge gained from this survey would help in improving our understanding of healthhealth
related quality of life, work productivity, treatment satisfaction, and treatment preferences of
individuals living with MS. The results of this survey may also help clinicians and other
healthcare professionals provide better treatment and care for individuals with MS.
Please find enclosed herewith a Walmart gift card worth $25 as a token of our
appreciation for your participation
ipation in our survey. You can use this gift card on Wal
Walmart.com,
SamsClub.com, or any Walmart store or Sam's Club location.

Thank you once again for your time and contribution toward a greater understanding of
the health matters of individuals with MS.
Sincerely,
Abhijeet Bhanegaonkar MPH
Ph.D. Candidate
Department of Pharmaceutical Systems and
Policy
WVU School of Pharmacy

S. Suresh Madhavan, MBA, Ph.D.
Professor and Chair
Department of Pharmaceutical Systems and Policy
WVU School of Pharmacy
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